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“Burden of Breast Cancer and Associated Health and Economic Outcomes in Elderly 
Women in West Virginia: Comparison with National Estimates” 
 
Ami Maulik Vyas 
 
 
West Virginia (WV) which is the only state which lies entirely in Appalachia and which 
is predominantly rural and medically underserved region, has lower incidence of breast cancer 
(BC) but a higher BC-related mortality as compared to the national averages in elderly women 
age 65 and above.  This may be due to lower mammography utilization in these rural elderly 
women, limited physical access to services, shortage of healthcare professionals and services, 
and untimely and/or inappropriate care.  This is dearth of epidemiological studies that have 
focused on understanding the factors associated with these disparities among these rural and 
underserved population such as WV.  The purpose of this project was to do a detailed evaluation 
of burden of BC and its associated health and economic outcomes in elderly women in WV, and 
to compare these estimates with the national estimates.  Three retrospective observational studies 
were conducted using West Virginia Cancer Registry-Medicare and Surveillance, Epidemiology, 
and End Results (SEER)-Medicare linked datasets for the years 2002-2007.  In the first study, 
persistence with mammography screening and its effect on stage at BC diagnosis was 
investigated for the elderly rural WV women and was compared to the national estimates from 
SEER-Medicare data.  The study found no significant differences in the representation of disease 
between WV-Medicare and SEER-Medicare cohorts even after controlling for persistence with 
mammography screening.  In the second study, timeliness of BC care in regards to diagnosis and 
treatment as per the published opinion-based recommendations and its effect on chances of being 
alive at the follow-up period was determined for the WV-Medicare cohort and then was 
compared to the SEER-Medicare cohort.  The study found that the WV-Medicare cohort was 
significantly less likely to receive timely diagnosis of BC as per recommendations when 
compared to the SEER-Medicare cohort.  However, there were no significant differences 
between these cohorts for the timely treatment of BC.  Also, delayed diagnosis was not 
associated with poorer prognosis in the WV-Medicare cohort.  In the third study, average total 
healthcare costs in the initial phase of 12-months following BC diagnosis and costs by types of 
specific services were estimated for the WV-Medicare cohort and these were compared to the 
national estimates derived from the SEER-Medicare cohort.  This study reported that average 
total healthcare costs, inpatient costs and physician services costs were significantly lower for the 
WV-Medicare cohort as compared to the SEER-Medicare cohort.  Also, the decomposition 
analyses only explained total 16% of the differences in the average costs due to the cohorts’ 
characteristics.  Overall, the findings of this project highlight the importance of persistence with 
mammography screening and timely BC care in the elderly, rural and underserved women 
diagnosed with BC.  Moreover, these studies can serve as a foundation for larger studies aimed at 
decreasing BC disparities in a rural and geographically challenged state such as WV, through the 
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Breast Cancer Overview 
Breast cancer (BC) is a malignant tumor that starts in the cells of the breast.  A malignant 
tumor is a group of cancer cells that invade surrounding tissues of the breast or metastasize to 
distant areas of the body.  BC is the most common cancer in women and is the second leading 
cause of cancer death in women in the United States (US).  About 1 in 8 (12%) women in the US 
will develop invasive BC during their lifetime.  According to the 2014 statistics by American 
Cancer Society, it is estimated that about 232,670 new cases of invasive BC, and about 62,570 
new cases of carcinoma in situ (CIS) will be diagnosed, and 40,000 women will die from BC in 
the US 
1
.   
Risk factors for Breast Cancer 
2
 
There are various modifiable and non-modifiable factors which affect a woman’s chance 
of developing BC.  Some of the non-modifiable risk factors increasing a woman’s risk of 
developing BC are gender (female), advanced age, family history of BC, personal history of BC, 
early menarche and late menopause, inherited genetic mutations (BRCA1/BRCA2 or others), 
having dense breast tissue, some benign breast conditions, previous chest radiation for other 
malignancies, and diethylstilbestrol exposure.  Modifiable risk factors associated with the 
development of BC in women include nulliparity, delayed child bearing, no full-term 
pregnancies, never breastfed, oral contraceptive use, post-menopausal hormone therapy, obesity, 




Breast Cancer Epidemiology 
BC incidence and mortality rates vary significantly by age.  Based on 2005-2009 
Surveillance, Epidemiology and End Results (SEER) statistics, the median age at diagnosis and 
mortality due to BC is 61 and 68 years, respectively 
3
.  Also, 41% of the new BC cases and 
57.4% of the BC deaths occur in women age 65 and above 
3
.  The overall incidence of BC in 
women below 65 years of age is 82.97 per 100,000 and is 421.30 per 100,000 women in those 
above age 65 
3
.  The overall mortality from BC is 11.15 per 100,000 women for those less than 
65 years of age and is 98.64 per 100,000 women in those above age 65 
3
.  Furthermore, older 
women age 65 and above have a greater burden of BC as they are diagnosed at advanced stages 
and with larger tumors impacting their survival 
4
. 
Mammography Screening  
 
Screening tests can find cancers in early stages before they start to cause symptoms and 
hence help in reducing cancer-related mortality.  Mammography screening is considered to be 
the ‘gold standard’ for women at average risk and it enables BC detection at an early stage, when 
the treatment is most effective and tends to require less intense systemic and local therapies 
5,6
.  
Several clinical trials have shown that mammography screening reduces BC-related mortality by 
20-35% in women age 40-69 years of age 
6-10
.  Also, a recent Cochrane review reported that 
mammography screening reduces relative risk in BC mortality by 15% with 0.05% reduction in 
absolute risk 
11
.   
Women diagnosed with BC who have had a screening mammogram within the previous 
two years are significantly less likely to have late-stage disease 
12
.  However, in 2010, only 64% 
of women age 65 and above had a mammography screening within the previous two years as 
4 
 
compared to 73% of women age 50-64 years 
2
 even though annual screening mammograms are 
recommended and covered by both Medicare and Medicaid. 
Breast Cancer and Mammography Screening in West Virginia 
 
West Virginia (WV) is the only state that lies entirely in Appalachia, a region which is 
predominantly rural and medically underserved, characterized by high poverty rates, low levels 
of education, an aging population, high rates of chronic disease, and poor health behaviors 
13-16
.  
For 2009, WV was reported to have a lower incidence of BC (112.6 vs. 122.9 nationally) but a 
higher BC-related mortality (23.3 vs. 22.2 nationally) 
17,18
.  Also, WV is reported to have higher 
rates of advanced and unstaged BC 
19-23
, which has been attributed to lower mammography 
screening rates of women in WV 
20-24
.  In 2010, WV was ranked 48
th
 among US states for 
women having mammography screening within the past two years 
25
.  In 2008, WV was ranked 
sixth nationally in BC deaths 
26,27
. 
In WV women age 65 years and above, BC accounted for 12% of all the incident cancer 
cases 
28
 and 5.3% of all cancer deaths 
29
.  For 2009 among women age 65 and older, WV had 
lower incidence of BC (372.8 per 100,000 vs. 411.7 per 100,000) but higher BC-related 
mortality (110.4 per 100,000 vs. 98.6 per 100,000) 
17,18
 as compared to the national estimates.  
This may be attributed to numerous factors such as lower mammography screening rates in these 
elderly women 
21-23,30
, limited physical access to services, shortage of healthcare professionals 
and services 
31
, and untimely BC care.  These disparities also indicate that elderly women 






NEED FOR STUDY 
Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis 
 
Though mammography screening has been shown to reduce BC mortality by 20-35% in 
the average-risk women age 40-69 years 
6-10
, it is not clearly evident whether or not 
mammography screening is beneficial in older women.  This is because very few screening trials 
assessing the benefits of mammography screening have included women aged 70 and above 
32
.  
Moreover, there is a deficit of evidence-based guidelines for mammography screening in elderly 
women.  Current US-based guidelines about screening mammography 
33-35
 have no upper age 
limit set for the procedure and suggest woman should have mammography screening as long as 
she is in good health.  Elderly women age 65 and above have a greater burden of BC as cancer 
tends to be found at advanced stages with larger tumor sizes, and thereby leading to poorer 
survival 
4
.  Additionally, the literature has also reported that these women are less likely to utilize 
mammography screening as compared to their younger counterparts 
33,36,37
.  In 2010, 64% of 
women age 65 and above had a mammography screening within the previous two years as 
compared to 73% among women age 50-64 years 
33
.  Various studies have demonstrated the 
benefits of mammography screening utilization in women age 65 and above on stage at BC 
diagnosis, an important predictor of survival 
38-41
.  Yet, these studies have limitations in terms of 
only including younger women, utilizing data from fewer cancer registries or utilizing data from 
limited time period before BC diagnosis, and not effectively distinguishing screening and 
diagnostic mammography claims, an inherent problem with Medicare claims data.   
Very limited information is available about the effect of mammography screening and 
stage at BC diagnosis among elderly Medicare beneficiaries diagnosed with BC from rural 
settings and non-SEER Medicare states.  With lower incidence of BC but higher BC-related 
6 
 
mortality in elderly WV women and lower mammography screening rates in these women, there 
is a vital need to determine the association between persistence with mammography screening 
and stage at BC diagnosis.   
Timeliness of Care among Elderly Women Diagnosed with Breast Cancer 
 
 Though BC is a major health issue and the second cause of cancer-related deaths in 
women in the US, measuring quality of care delivered to women diagnosed with BC is extremely 
challenging.  Timeliness of care i.e. prompt diagnosis after detecting an abnormality in the breast 
and prompt initiation of the treatment after BC diagnosis is an important component of high-
quality BC treatment.  Providing timely care to BC patients is significant to both patients and 
primary providers in order to reduce BC-related mortality 
42,43
.  Despite the widely accepted 
benefit of timely care in BC patients, the US-based guidelines have yet to define an appropriate 
time frame from presentation of abnormality in a breast to confirmed BC diagnosis and from BC 
diagnosis to the initiation of the treatment.  However, other international oncology organizations 
such as European Society of Breast Cancer Specialists (EUSOMA) and National Health Service 
of United Kingdom have published professional opinion-based recommendations.  Each group 
provides recommendations on time intervals between events such as presentation of abnormality 
to diagnosis of BC 
44
 and between BC diagnosis to the initiation of the treatment 
45
, respectively.   
Various studies regarding timeliness of BC care have been conducted in the last decade in 
the US 
46-54
, but no consensus exists regarding an appropriate time from diagnosis and to 
treatment.  Also, none of these studies have followed any published opinion-based 
recommendations to appropriately define timely diagnosis and treatment.   
As elderly women age 65 years and above have higher BC incidence and mortality and 
are more likely to have advanced stage disease at diagnosis 
3,4
, it is highly likely that delayed 
7 
 
diagnosis and/or delayed treatment may negatively affect the prognosis of the disease, and hence 
their survival.  Previous literature has also reported that delay in diagnosis is a major factor 
contributing to the poor survival in elderly women diagnosed with BC 
4
.  Hence, it is 
exceedingly important to determine timeliness of BC care based on the published opinion-based 
recommendations among elderly women with BC in the US.  In addition, as WV had a lower 
incidence of BC among women age 65 and above but higher BC-related mortality 
17,18
 as 
compared to the national estimates, it is possible that the timeliness of care may be one of the 
important contributors to these disparities.  Therefore, a study comparing the timeliness of BC 
care among elderly WV women diagnosed with BC to the national estimates may help begin to 
understand these disparities.    
Total Healthcare Costs of Breast Cancer in the Initial Phase (12-months) After Diagnosis 
The lifetime per-patient direct medical care cost estimates of BC ranged from $20,000 to 
$100,000 for the base cost year from 1984 to 2003 
55
.  The direct medical costs of initial and 
terminal care for women with BC are reported to be significantly higher than that of the 
continuing care on a per unit time basis 
55
.  This is because the costs of BC care are substantial 
during the initial care (12-months) period encompassing the time from diagnosis to surgery, 
radiation and adjuvant systemic therapy which constitute the major cost components in cancer 
therapy 
56-59
.   
To date, a majority of the studies estimating total healthcare costs during the initial period 
after BC diagnosis in elderly women are either outdated or have utilized SEER-Medicare data 
from fewer cancer registries and states/regions or have not stratified the results by stage at 
diagnosis, comorbidity and type of initial treatment.  Besides, very limited information is 
available about the healthcare costs in elderly women diagnosed with BC from rural settings and 
8 
 
from non-SEER states, such as WV.  As WV has a lower incidence of BC but a higher BC-
related mortality among women age 65 and older 
17,18
 as compared to the national estimates and 
with the increasing median age of the population and higher BC cases at advanced stages, it may 
be likely that healthcare costs during the initial period among elderly WV women diagnosed with 
BC may be higher as compared to the national estimates.  Thus, a study comparing the healthcare 
costs during the initial period of 12-months among elderly WV women diagnosed with BC with 
that of the national estimates is essential to understand any such disparities.  This data may aid in 
planning for healthcare costs and may facilitate resource allocation in the future.  
SPECIFIC AIMS AND OBJECTIVES 
 
The specific aims and objectives of the project are: 
 
Specific Aim 1:  To determine the association between persistence with mammography 
screening and stage at BC diagnosis among Medicare fee-for-service (FFS) beneficiaries in WV 
and compare it with national estimates from the SEER-Medicare data 
Objective 1:  To determine the proportion of Medicare FFS women beneficiaries with incident 
BC persistent with mammography screening in WV and compare it with national estimates from 
the SEER-Medicare data 
Objective 2:  To determine the stage at BC diagnosis among women Medicare FFS beneficiaries 
in WV by mammography screening persistence and compare it with the national estimates from 
the SEER-Medicare data 
Objective 3:  To determine the association between persistence with mammography screening 
and stage at BC diagnosis among women Medicare FFS beneficiaries in WV,after controlling for 
predisposing factors (age), enabling factors (median household income, education level), need 
factors (co-occurring chronic conditions), healthcare use (number of primary care physicians 
9 
 
(PCP) visits in five years before BC diagnosis) and external healthcare environmental factors 
(location of residence and number of hospitals offering BC screening/mammography services in 
the area of residence), and compare it with the national estimates from the SEER-Medicare data 
Specific Aim 2:  To determine the timeliness of BC care based on published recommendations 
among Medicare FFS beneficiaries in WV and compare it with the national estimates from the 
SEER-Medicare data 
Objective 1:  To determine time to diagnosis and treatment among WV women Medicare FFS 
beneficiaries and compare them with the national estimates from the SEER-Medicare data 
Objective 2:  To determine the proportion of WV women Medicare FFS beneficiaries receiving 
timely BC care based on published recommendations and compare it with the national estimates 
from the SEER-Medicare data 
Objective 3:  To identify the factors associated with receipt of timely BC care based on published 
recommendations among WV women Medicare FFS beneficiaries and compare them with the 
national estimates from the SEER-Medicare data 
Objective 4:  To determine the association between receipt of timely BC care based on published 
recommendations and survival among WV women Medicare FFS beneficiaries, and compare it 
with the national estimates from SEER-Medicare data 
Specific Aim 3:  To determine average total healthcare costs and costs by type of specific 
services during the initial phase of 12 months following an incident diagnosis of BC among 
Medicare FFS beneficiaries in WV and compare it with the national estimates from SEER-
Medicare data 
Objective 1:  To determine average total healthcare costs in initial phase among Medicare FFS 
beneficiaries in WV, and compare it with the national estimates from the SEER-Medicare data 
10 
 
Objective 2:  To determine average total healthcare costs by types of specific services in the 
initial phase among Medicare FFS beneficiaries in WV, and compare them with the national 
estimates from the SEER-Medicare data 
Objective 3:  To determine the predictors of average total healthcare costs in the initial phase 
among Medicare FFS beneficiaries in WV and compare them with the estimates from SEER-
Medicare data 
Objective 4:  To determine the magnitude of differences in the average total healthcare costs in 
the initial phase between Medicare FFS beneficiaries in WV and those from the SEER-Medicare 
using decomposition analysis 
CONCEPTUAL FRAMEWORK 
The Andersen Behavioral Model for Health Services Utilization (Andersen model) was utilized 
as the conceptual model in these studies 
60,61
.  This model that has been used for decades in 
predicting health services utilization in population-based studies postulates that healthcare 
services utilization is the function of the predisposition of individuals to use services, factors 
which enable or impede use, the need for care, healthcare use, and external environmental.  This 
model is one of the most frequently used conceptual frameworks for analyzing individual’s 
utilization of health care services (Figure 1.1).   
 Predisposing factors such as age, race, and enabling factors such as census tract annual 
household income and census tract education level were included in the model.  Need-related 
factors included in the model were comorbidities, mental conditions, stage at diagnosis, grade of 
tumor, estrogen-receptor status, and size of tumor.  The later four variables were included only in 
Aims 2 and 3.  Healthcare use consisted of persistence with mammography screening, primary 
care physicians visits, type of initial treatment, and inpatient use.  The later two variables were 
11 
 
included only in Aims 2 and 3. External health care environment factors included in the model 
were location of residence and number of hospitals offering BC screening and oncology related 
services.  Using this Andersen Behavioral model of healthcare services utilization provides a 
strong theoretical framework to identify the factors which influence stage at BC diagnosis (Aim 
1), timeliness of BC care (Aim 2), and total healthcare costs in the initial period of one year (Aim 
3).   
SIGNIFICANCE 
 
Aim 1 results from this study will help understand the disparities in stage at the time of BC 
diagnosis by persistence with mammography screening among Medicare FFS beneficiaries from 
rural setting, such as WV, and how this association varies from national estimates.  Aim 2 results 
will help to identify disparities in the timeliness of BC care and the factors contributing to timely 
diagnosis and treatment and how timely care affect survival among elderly Medicare FFS 
beneficiaries diagnosed with BC from a rural setting such as WV, and compare them with the 
national sample estimates.  Aim 3 results will help to understand average total healthcare costs in 
the initial phase, and to what extent age, race, location of residence, type of treatment, 
comorbidity burden and clinical variables affect these costs in elderly Medicare FFS 
beneficiaries in WV diagnosed with BC and variation from the national estimates will also be 
obtained.  In addition, comparing average total healthcare costs among elderly Medicare 
beneficiaries in WV with incident BC to the national sample will help to determine whether or 
not these costs were higher in a rural setting such as WV with higher median age and where the 
majority of the elderly women are diagnosed at advanced stages of BC.  Overall, this project laid 
the foundation for larger studies aimed at decreasing BC disparities in a rural and geographically 
12 
 
challenged state such as WV, through the development of strategies and interventions to foster 
early detection and timely treatment of BC among elderly women.   
LIMITATIONS 
 
Since the study utilized administrative claims data, the limitations of these studies include 
selection bias, misclassification and coding errors.  Data on beneficiaries from the Medicare 
managed care program, and uninsured population was not be used, thus the study results may be 
generalizable only to FFS beneficiaries.  Since information on each patient’s socio-economic 
status is not available with SEER-Medicare, the county level census tract median household 
income and education level were utilized 
62
.  Medicaid claims for dual-eligible Medicare 
beneficiaries in the SEER-Medicare data are not available; therefore, we limited our comparisons 
of costs to those incurred only by Medicare for beneficiaries diagnosed with cancer in WV and in 
SEER-Medicare.  Any screening mammograms obtained outside the Medicare program such as 
from free mammography screening programs are not captured by Medicare and hence may affect 
the precision of the estimates.  This may not be a significant limitation as Medicare is the 
primary health insurer for the older adult population.  Any genetic factors, family history of BC, 
and psychosocial factors such as perceived risk and knowledge about mammography screening 
and BC, affecting the screening behavior and incidence of BC are not captured by this database 
and hence may affect the precision of the estimates.  As per the literature, the FFS beneficiaries 
tend to be sicker than those in managed care, thus the costs may be skewed for the beneficiaries.  
The costs reported do not include out-of-pocket costs, and hence do not represent total cost of 
care during initial one year period.  Moreover, costs associated with lost productivity and other 
non-medical costs which constitutes important economic burden are not captured by Medicare 
and hence are not included.  As Medicare data on prescription drugs is not available before 2007, 
13 
 
the costs associated with adjuvant therapies with prescription drugs such as Tamoxifen were not 
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ASSOCIATION BETWEEN PERSISTENCE WITH MAMMOGRAPHY SCREENING 
AND STAGE AT DIAGNOSIS AMONG ELDERLY WOMEN DIAGNOSED WITH 
BREAST CANCER  
INTRODUCTION 
Breast Cancer 
Breast cancer (BC) is the most common cancer and the second leading cause of cancer 
death in women in the United States (US).  For year 2014, about 232,670 new cases of invasive 
BC, and about 62,570 new cases of carcinoma in situ (CIS) will be diagnosed, and 40,000 
women will die from BC in the US 
1
.   
BC incidence and mortality rates vary significantly by age.  Based on Surveillance, 
Epidemiology and End Results (SEER) statistics for 2005-2009, the median age at diagnosis and 
mortality due to BC was 61 and 68 years, respectively 
2
.  Also 41% of the new cases of BC were 
diagnosed, and 57.4% of the BC deaths occurred in women age 65 and above 
2
.  More than half 
of incident BC diagnoses occur in women age 65 and above 
3
.  The overall incidence of BC for 
2005-2009 was 82.97 per 100,000 in women age below 65 years and was 421.30 per 100,000 in 
women age 65 and above.  The overall mortality from BC for 2005-2009 was 11.15 per 100,000 
in women below 65 years of age and was 98.64 per 100,000 in women age 65 and above 
2
.  
Moreover, elderly women age 65 and above have a greater burden of BC as tumor in these 









Mammography screening is considered the ‘gold standard’ for women at an average risk 
to detect BC at an early stage, when the treatment is less aggressive and most effective 
5,6
.  
Mammography screening has demonstrated a reduction in BC-related mortality by 20-35% in 
average-risk women age 40-69 years of age 
6-10
.  Also, women diagnosed with BC who have had 
a mammography screening within the previous two years are significantly less likely to have 
late-stage disease 
11
.  However, in 2010 only 64% of women age 65 and above have had 
mammography screening within the past two years as compared to 73% among women age 50-
64 years 
12
 even though annual screening mammograms are covered by both Medicare and 
Medicaid.  This lower percentage may be partly due to the uncertainty regarding the frequency 
and upper age limit to avail mammography screening as reflected in the BC screening guidelines.  
The US Preventive Service Task Force recommends biennial mammography screening for 
women in age group 69 to 74 years, but reported insufficient evidence for mammography 
screening for women age above 74 years 
13
.  In contrast, the American Cancer Society 
recommends annual mammography screening with no set upper age limit for women till her life 
expectancy is at least five years 
14
.  In absence of no direct evidence of beneficial effects of 
mammography screening and with suggested potential and immediate harms of mammography 
screening in elderly women age 75 and older, this group encounters contrasting 
recommendations and guidelines for mammography screening which may affect their screening 
behavior thereby leading to poorer breast cancer outcomes. 
Breast Cancer and Mammography Screening in West Virginia 
West Virginia (WV), the only state that lies completely in Appalachia is a largely rural 
and medically underserved region in the US characterized by high poverty rates, low levels of 
23 
 
education, aging population, high rates of chronic diseases, and poor health behaviors 
15-18
.  WV 
is reported to have higher rates of advanced and unstaged BC 
19-23
, which has been attributed to 
lower mammography screening rates in women in WV 
20,21,24,25
.  Additionally, WV was ranked 
sixth nationally in BC deaths in 2008 
26,27
. 
In WV women age 65 years and above, BC accounted for 12% of all the incident cancer 
cases 
25
 and 5.3% of all cancer deaths 
28
.  For 2009 among women age 65 and older, WV had 
lower incidence of BC (372.8 per 100,000 vs. 411.7 per 100,000 nationally) but higher mortality 
(110.4 per 100,000 vs. 98.6 per 100,000 nationally) 
29,30
 as compared to the national estimates.  
The authors of various studies have argued that low mammography screening rates in WV 
women may be one of the significant factors responsible for this disparity 
21,25,31
. 
Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis 
Although mammography screening has been reported to reduce BC mortality by 20-35% 
in women age 40-69 years 
6-10
, it is not yet clear whether or not mammography screening is 
beneficial in older women.  This is because very few screening trials evaluating the benefits of 
mammography screening in women have included women aged 70 and above 
32
.  Elderly women 
age 65 and above have a greater burden of BC since it is found at more advanced stages and with 
larger tumor sizes thereby leading to poorer survival 
4
.  Also, though these women are more 
vulnerable to BC, they are less likely to utilize mammography screening 
33,34
.  In 2010, 64% of 
women age 65 and above have had mammography screening within the previous 2 years as 
compared to 73% among women age 50-64 years 
12
.  Without clear scientific evidence of 
benefits of mammography screening in older women, physicians are left with the decision 
whether or not to recommend mammography screening to these elderly women.  Physicians have 
24 
 
several mammography screening guidelines from which to choose for this expanding aging 
population, when most of the current US-based guidelines have no upper age limit set up. 
Even though reducing BC-related mortality is the ultimate goal of mammography 
screening, intermediate measures such as stage at diagnosis are useful to evaluate the utility of 
screening 
35,36
.  In elderly women age 65 and above, various studies have demonstrated the 
benefits of mammography screening utilization on an important predictor of survival, stage at 
BC diagnosis.  Two studies which used Surveillance Epidemiology and End Results (SEER)-
Medicare database reported that mammography use decreased with advancing age at diagnosis, 
and older women who undergo regular mammography were diagnosed with an earlier stage of 
disease 
37,38
.  However, these studies utilized the mammography screening data from only two 
years before BC diagnosis, which may have failed to capture the effect of persistence with 
mammography screening on the stage at BC diagnosis.  Also, a study by McCarthy et al. utilized 
SEER data from only three registries which may limit the generalizability of the study findings 
37
.  A study which utilized 5-years mammography utilization data from all the SEER registries 
reported that regular mammography screening was associated with earlier stage at BC diagnosis, 
though it focused only on women age 80 and above 
39
.  A systematic review of routine 
mammography screening demonstrated that regular mammography screening was associated 




Thus, most of the studies evaluating the association between mammography screening 
utilization and stage at BC diagnosis have been conducted using data from either a few SEER-
Medicare registries, or data for limited time period of two years before BC diagnosis, or among 
women age 80 and above.  Moreover, the major limitation with all these previous studies is that 
25 
 
the authors did not use any model or technique to distinguish screening from diagnostic 
mammograms which is one of the key concerns with Medicare or any administrative claims data.  
A study by Freeman et al. 
41
 reported that challenges persist in distinguishing screening 
mammograms from the diagnostic ones with the Medicare claims data as many screening 
procedures may be billed as diagnostic procedures as the later are reimbursed at higher level.  
The authors of a recently published study have developed and suggested a 3-step algorithm with 
higher sensitivity (99.7%) and higher positive predictive value (97.4%) to distinguish between 
screening and diagnostic mammograms using Medicare data linked to a cancer registry 
42
.  In the 
absence of strong evidence supporting beneficial effects of mammography screening and hence 
no current guidelines supporting mammography screening in older women and in absence of 
proper studies focusing on this crucial issue, overall there is a vital need to determine the 
association between mammography screening and stage at BC diagnosis among elderly women 
age 65 and above, that clearly distinguishes between screening and diagnostic mammograms, 
from a large number of SEER-Medicare registries, with a longer follow-up time period of at least 
five years before BC diagnosis to capture persistence to mammography screening.   
In addition, SEER-Medicare data represents only 17 cancer registries and states/regions 
and reflects a population more likely to be residing in urban setting 
43
.  Very limited information 
is available about the use of mammography screening and stage at BC diagnosis among elderly 
Medicare beneficiaries diagnosed with BC from rural settings and from non-SEER Medicare 
states.  In contrast to population characteristics prevalent in SEER-Medicare areas, a large 
majority of the population in WV is white and a significant proportion resides in rural areas.  For 
2009, WV had a lower incidence of BC among women age 65 and older (372.8 per 100,000 vs. 





compared to the national estimates.  The proportion of WV women who have had a mammogram 
in the past two years increased with increase in age until 64 years, but the trend reversed for 
those who were age 65 and above 
24
.  Moreover, the overall mammography screening rates in 
WV women was also lower than the national estimates 
24
.  Due to higher BC mortality in women 
age 65 years and above in WV as compared to national estimates, there is a need to determine 
the association between persistence with mammography screening and stage at BC diagnosis in 
elderly WV women and compare this with the national estimates.   
Hence, the purpose of the study is to determine the persistence with mammography 
screening in WV Medicare fee-for-service (FFS) women beneficiaries diagnosed with first 
incident BC and compare it with national estimates using SEER-Medicare data and to determine 
the association between persistence with mammography screening and stage at BC diagnosis in 
these WV women and compare it with the national estimates, after controlling for predisposing 
factors (age), enabling factors (median household income, education level), need factors (co-
occurring chronic conditions), healthcare use (number of primary care physicians (PCP) visits in 
five years before BC diagnosis) and external healthcare environmental factors (location of 






West Virginia Cancer Registry-Medicare-Area Resource File linked dataset 
Established by the West Virginia Department of Health and Human Resources in 1993, 
the West Virginia Cancer Registry (WVCR) is a state-level cancer registry which provides 
information on cancer incidence and mortality in West Virginia (WV) 
44
.  The registry collects 
27 
 
and provides data on the primary site of cancer, tumor grade, date and stage of diagnosis, date 
and cause of mortality, and demographics such as age, gender, race, and also zip code 
information (for location of residence).  The de-identified linked WVCR-Medicare dataset was 
established at West Virginia University (WVU) in full compliance with the WVU Institutional 
Review Board and HIPPA requirements 
45
.  The WVCR file served as the case source file, and 
individuals who were aged ≥ 65 years and diagnosed with cancer between the January 1, 2002 
and December 31, 2007 were extracted from this file.  The Social security numbers (SSN) for 
these individuals was then provided to the CMS by the WVCR, using which the CMS identified 
the corresponding Health Insurance Claim (HIC) number.   To extract information on the 
individuals as Medicare beneficiaries, a “crosswalk” file is created using the HIC which allows 
for linkage across the WVCR and the Medicare.  Individuals with a missing SSN were excluded 
from the linkage.  The Area Resource File (ARF) was linked to the WVCR-Medicare dataset 
using the state and county FIPS codes for each beneficiary to extract the county level 
information on the availability of healthcare facilities, healthcare providers, and socioeconomic 
characteristics of the region’s population. 
SEER-Medicare-Area Resource File linked dataset 
The SEER-Medicare linked dataset provides population-based information on cancer-
related epidemiologic and health services research.  The SEER-Medicare program collects 
information on newly diagnosed cases of cancer from 17 population-based tumor registries 
which in turn collect information from several sources including hospitals, outpatient clinics, 
laboratories, private practitioners, laboratories, hospices, autopsy reports and death certificates.  
The SEER-Medicare data represents approximately 26% of the US population.  The SEER part 
of the SEER-Medicare data is in the form of a tailored file known as the Patient Entitlement and 
28 
 
Diagnosis Summary File (PEDSF).  PEDSF contains one record per person for individuals in the 
SEER database who have been matched with Medicare enrollment records.  These files provide 
diagnostic information for up to 10 diagnosed cancer cases (including date of cancer diagnosis, 
cancer sub-site, cancer stage at diagnosis, tumor size, histology, grade), and information on the 
first course of cancer related treatment (surgery and radiation provided in the first 4 months after 
diagnosis) for each individual.  The PEDSF additionally includes information on the median 
household income and education level for each individual based on their census tract and zip 
code data.  
The Medicare files that are a part of the SEER-Medicare linked dataset provide 
information about any health care utilized by individuals age 65 and above who are enrolled in 
and are covered under the Medicare program.  These files have claims from the inpatient, 
outpatient, physician, home health, and hospice care utilized by individuals enrolled in the 
program.  The linkage of the SEER data with the Medicare data, and formation of the SEER case 
number involves matching individuals across the two files using an algorithm based on a match 
of SSN, name, sex, and date of birth.  The linkage process is described elsewhere 
43
.  The Area 
Resource File (ARF) was linked to the SEER-Medicare dataset using the state and county 
Federal Information Processing Standards (FIPS) code for each beneficiary to extract the county 
level information on the availability of healthcare facilities and healthcare providers. 
Study Design 
 This study utilized a retrospective observational cohort design to assess the association 
between persistence with mammography screening and stage at diagnosis among Medicare FFS 







The two study cohorts consisted of all women from WVCR-Medicare-ARF linked 
dataset and SEER-Medicare-ARF linked dataset, age 70 and above at the first primary diagnosis 
of incident BC between January 1, 2007 and December 31, 2007.  Since mammography 
screening persistence during the period of five years before BC diagnosis was to be determined, 
women age 70 and above who were continuously enrolled in Medicare parts A and B for at least 
60 months before BC diagnosis and till the month of BC diagnosis, and who were not enrolled in 
health maintenance organizations (HMOs) at any time during the study period were included in 
the study.  Women with a previous cancer diagnosis, unknown or missing BC stage information, 
and who were diagnosed via death certificate or autopsy were excluded from the study.  BC 
diagnosis codes were based on the primary site and International Classification of Diseases, 9
th
 
edition Clinical Modification (ICD-9-CM) codes 174.xx, 233.0x, 238.3x, and 239.3x. 
According to the WVCR-Medicare-ARF linked dataset, 661 women were diagnosed with 
BC from January 1, 2007 to December 31, 2007.  The following women were excluded from the 
final study population: 168 women who were younger than 70 years at diagnosis, 99 women with 
any previous cancer diagnosis, 7 women who were diagnosed with BC during death or autopsy, 
56 women for whom BC stage information was unknown or missing, 32 women who were not 
continuously enrolled in Medicare parts A and B for 5 years before diagnosis, and 72 women 
who were members of HMO any time during the study follow-up period.  From the remaining 
227 women, only 6 women (2.6%) belonged to ‘other’ race which resulted in very small cell-size 
for stage at diagnosis categories, and hence were removed from the analyses.  Hence, the cohort 
of 221 WV women was included in the final analyses. 
30 
 
According to the SEER-Medicare-ARF linked dataset, 27,781 women were diagnosed 
with BC from January 1, 2007 and December 31, 2007.  The following women were excluded 
from the final study population: 14,175 women who were younger than 70 years at diagnosis, 
721 women with any previous cancer diagnosis, 171 women who were diagnosed with BC 
during death or autopsy, 383 women for whom BC stage information was unknown or missing, 
770 women who were not continuously enrolled in Medicare parts A and B for 5 years before 
diagnosis, and 3,616 women who were members of HMO any time during the study follow-up 
period.  The remaining 7,945 SEER-Medicare women were eligible to be included in all further 
analyses to derive national estimates.   
Measures 
Dependent Variable: Stage at diagnosis:  BC stage at diagnosis was determined according to the 
SEER summary staging system which is a combination of the most accurate clinical and 
pathological documentation of the extent of disease 
46
 and which uses all the data in the medical 
record.  The variable was categorized as an ‘early stage’ consisting of carcinoma insitu and 




Key Independent Variable: Persistence with mammography screening:  There is ambiguity 
regarding the ability of Medicare claims data to distinguish screening from diagnostic 
mammograms.  Appropriately distinguishing screening mammograms from diagnostic 
mammograms is very crucial when assessing screening utilization using claims-based database 
48
.  No clear distinction between screening and diagnostic mammograms may affect 
measurement of the effect of mammography screening on BC-related outcomes using Medicare 
claims.  A recently published 3-step algorithm with high sensitivity (99.7%) and high positive 
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predictive value (97.4%) of a screening designation was utilized to classify screening 
mammograms from diagnostic mammograms 
42
.    
After capturing the claims for all the mammograms, this 3-step algorithm was applied 
42
.  
It had the following sequential steps:  
Step 1: To identify if women had a mammogram in the previous 9 months (<= 270 days):  If a 
woman had a mammogram within 9 months then those mammograms were removed.  If a 
woman did not a mammogram within 9 months then those mammograms led to step 2. 
Step 2: To identify if the Healthcare Common Procedure Coding System (HCPCS) code for a 
mammogram was for ‘screening’ or ‘diagnostic’ purpose:  If the HCPCS code for a mammogram 
was for ‘screening’ purpose then those mammograms were considered to be screening 
mammograms and were utilized to determine persistence with mammography screening.  If the 
HCPCS code for a mammogram was for ‘diagnostic’ purpose then those mammograms led to 
step 3. 
Step 3: If identify if a woman had any BC-related symptom 349 days prior to ‘diagnostic’ 
mammogram: If a woman had a BC-related symptom within 349 days prior to diagnostic 
mammogram then those mammograms were removed.  While, if a women had a BC-related 
symptom beyond 349 days prior to diagnostic mammogram were utilized to determine 
persistence with mammography screening. 
All the mammograms which had HCPCS codes for ‘screening’ in step 2 and those for which 
prior BC-related symptom was beyond 349 days in step 3 were considered to be actual screening 
mammograms and were utilized to determine persistence with mammography screening for each 
woman in the study cohorts.  Using this algorithm improved the precision of estimates for this 
study.   
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The key independent variable for this study was persistence with mammography 
screening defined in the literature as having had at least three consecutive mammograms as per 
the screening guidelines 
49
.  Based on the number of screening mammograms a woman had 
during the five years period before BC diagnosis, women were categorized as Non-persistent 
users (with 0-2 screening mammograms), and Persistent users (with three or more screening 
mammograms).  As per the recently published study, older women above 65 years of age have 
similar risk of advanced stage of BC with biennial screening mammography as compared to 
annual screening mammography 
50
.  Hence, persistent users represented a population who have 
had annual to biennial screening mammography before BC diagnosis. 
Other Independent Variables:  To identify the factors that contributed to an early stage at BC 
diagnosis associated with persistence with mammography screening, the Andersen behavioral 
healthcare services utilization model was used 
51,52
.  Based on this model, the independent 
variables were grouped into predisposing factors, enabling factors, need-related factors, factors 
associated with healthcare use, and external healthcare environmental factors (Figure 2.1).   
Predisposing factors consisted of age at BC diagnosis (70-74, 75-79, 80 and older), race 
(white, other), while enabling factors included census tract median household income of their zip 
code of residence (=<$35,000; >$35,000), and census tract percentage of people age >= 25 years 
with at least 4 years of college education (<15%, >=15%).  As individual level information on 
household income and education level were not available with both SEER-Medicare and WV-
Cancer Registry, census tract information for these two variables were utilized in this study.  
Need-related factor comprised of co-occurring chronic conditions during the twelve months 
before BC diagnosis which were identified from the Medicare files using the ICD-9 diagnosis 
codes.  Comorbidity scores were calculated using Charlson comorbidity index with macros 
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provided by the National Cancer Institute 
53-55
 and were categorized as 0 (no comorbidity), 1, and 
2+.  Healthcare use factors comprised of number of primary care physicians (PCP) visits in the 
five years before BC diagnosis.  Similar to previous research, PCP visits were derived from 
National Claims History (NCH) files using the Medicare provider specialty field found in NCH 
claims and the PCP included those in general practice (01), family practice (08), internal 
medicine (11), geriatric medicine (38), and multi-specialty group practice (70) 
56
.  The PCP visits 
were categorized into two groups (high, low) based on the median value.  External healthcare 
environmental factors included location of residence based on US Department of Agriculture 
rural-urban continuum codes (metro, urban, rural) and the number of hospitals with BC 
screening/mammography services in the area of residence for each woman derived from ARF 
file. 
Statistical Analyses        
 
Chi-square statistics for categorical variables and t-test test for continuous variables were 
used to determine significant differences in persistence to mammography screening categories 
across all the independent variables, for both the study cohorts.  The percentage of women with 
each stage of disease according to persistence with mammography screening was also calculated 
for both the study cohorts.  For each cohort, logistic regression was performed to determine the 
association between screening mammography persistence and an early stage of disease, after 
controlling for predisposing, enabling, need, healthcare use and external healthcare 
environmental factors.  In both the regressions, “late stage” was used as the reference group for 
the dependent variable.  As the sample size for the WV-Medicare cohort was very small as 
compared to the SEER-Medicare cohort and consisted of only white women, 10% of non-
Hispanic white women from each SEER-Medicare registry were randomly selected to make the 
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national cohort comparable to WV cohort.  This randomly selected sample had similar 
distribution of characteristics as the entire SEER-Medicare non-Hispanic white population (data 
not shown).  Hence, 708 women comprised of the SEER-Medicare cohort who were included for 
further analyses to determine the relationship between type of cohort (WV-Medicare and SEER-
Medicare) and an early stage of disease, after controlling for all the independent variables.  
Logistic regression was performed using “late stage” as the reference group for the dependent 
variable.  The fit of the regression models were tested by Pearson chi-square and likelihood ratio 
chi-square (deviance statistics) and Hosmer-Lemeshow goodness-of-fit statistic 
57
.  From the 
logistic regressions, the parameter estimates were transformed to odds ratios and their 
corresponding 95% confidence intervals were examined and the findings that were significant 
with p-values less than 0.05 levels are discussed.  All analyses were conducted within statistical 
analysis systems software SAS 9.3 (SAS
®
 version 9.3, SAS Institute Inc., Cary, NC, USA). 
RESULTS 
 
Description of the Study Cohorts by Persistence with Mammography Screening 
 
Table 2.1 characterizes WV-Medicare and SEER-Medicare cohorts by persistence with 
mammography screening in women age 70 and above, diagnosed with first primary incident BC 
in 2007.  For the WV-Medicare cohort, younger age at diagnosis was associated with screening 
mammography persistence.  However for SEER-Medicare cohort, younger age at diagnosis, 
being white, higher household income, residence in an area with higher proportion of the 
population with higher education, no or one co-occurring condition, and low PCP visits were 





Stage at Breast Cancer Diagnosis by Persistence with Mammography Screening 
Approximately, 51% of women in WV-Medicare cohort were persistent with 
mammography screening (Figure 2.2) as compared to 45.4% in the SEER-Medicare cohort 
(Figure 2.3).  Figure 2.4 describes disease stage according to persistence with mammography 
screening during five years before diagnosis for WV-Medicare cohort.  Among women who 
were not persistent with mammography screening, 31% were diagnosed with the late stage 
disease.  Among women who were persistent with mammography screening, only 12% were 
diagnosed with late stage disease.  Figure 2.5 describes disease stage by persistence with 
mammography screening during five years before diagnosis for the SEER-Medicare cohort.  
Among women who were not persistent with mammography screening, 39% were diagnosed 
with late stage disease.  Among women who were persistent with mammography screening, 17% 
were diagnosed with late stage disease.  This indicates that the WV-Medicare cohort had a larger 
proportion of women diagnosed at an early stage BC if they were persistent with mammography 
screening as compared to the SEER-Medicare cohort. 
Association between Persistence with Mammography Screening and Stage at Breast 
Cancer Diagnosis 
Table 2.2 describes the results of separate multivariate logistic regressions for the 
probability of an early stage disease for both the study cohorts.  For the WV-Medicare cohort, 
women who were persistent with mammography screening were four times more likely of being 
diagnosed at an early stage BC (Adjusted odds ratio (AOR) = 4.18, 95% confidence interval (CI) 
= 1.94-8.98) as compared to those who were not persistent with mammography screening.  No 
other factors significantly affected the probability of being diagnosed at an early stage in this 
sample.  For the SEER-Medicare cohort, women who were persistent with mammography 
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screening were significantly more likely to be diagnosed at an early stage BC (AOR = 1.44, 95% 
CI = 1.31-1.58) as compared to those who were not persistent with screening mammography.  
Among enabling factors, higher household income was significantly associated with more 
likelihood of women being diagnosed at an early stage disease (AOR = 1.19, 95% CI = 1.04-
1.35) as compared to those with lower household income.  Women who had higher PCP visits 
during five years before BC diagnosis were significantly more likely to be diagnosed at an early 
stage BC (AOR = 1.17, 95% CI= 1.06-1.28) as compared to those who had lower PCP visits. 
Description of the Study Cohorts  
Table 2.3 characterizes the significant differences in WV-Medicare and SEER-Medicare 
cohorts.  The two cohorts were significantly different from each other in terms of enabling 
factors such as census tract household income and census tract education level, and external 
healthcare environmental factors such as location of residence and number of hospitals with BC 
screening services in the area of residence.  Elderly women in WV diagnosed with BC were 
more likely to reside in rural areas, had lower census tract annual household income, had lower 
education levels, and had less access to BC screening centers as compared to those from the 
SEER-Medicare cohort. 
Differences in Stage at Breast Cancer Diagnosis between Study Cohorts in a Multivariate 
Framework 
Table 2.4 lists the results of the multivariate logistic regression for the probability of an 
early stage disease after combining both WV-Medicare and SEER-Medicare cohorts and 
controlling for the type of setting (WV-Medicare vs. SEER-Medicare) and other independent 
variables.  Women in WV-Medicare cohort were more likely to be diagnosed at an early stage 
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disease as compared to women in the SEER-Medicare cohort, however the association was not 
significant (AOR = 1.57, 95% CI = 0.97-2.55).   
DISCUSSION 
As per the literature to date, this is the first study which after appropriately identifying 
screening mammograms from the Medicare claims using a recently published algorithm, 
evaluated the association between persistence with mammography screening and stage at BC 
diagnosis in a rural state  such as WV and compared it with the national estimates derived from 
the SEER-Medicare data.  In the absence of data on persistence with mammography screening 
from a rural setting and from non-SEER-Medicare states, this study has filled a significant 
literature gap by addressing these issues and improving the precision of the estimates by 
appropriately identifying screening mammograms from the Medicare claims.  The findings of 
this study are consistent to the previous studies which reported that regular mammography 
screening or having had a mammography screening in one to two years before BC diagnosis was 
associated with earlier disease stage 
37,39,40,48
.   
Approximately 51% of elderly WV women diagnosed with BC were persistent with 
mammography screening as compared to 45% from those in the SEER-Medicare cohort.  Also in 
WV-Medicare cohort, approximately 89% of women with BC were diagnosed with an early 
disease if they were persistent with mammography screening as compared to 83% from the 
SEER-Medicare cohort.  Thus, the arguments made by the authors of the previous studies about 
lower mammography screening utilization in WV women as one of the contributing factors to 
late stage BC diagnosis 
20,24,31
 are conflicting with the findings of this study .  There may be 
other factors such as poor health status, family history of BC, BRCA gene mutation, untimely 
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and inappropriate care, that may be responsible for higher rates of late stage BC in elderly 
women in WV.   
Even though WV women were more likely to reside in rural regions, had lower income 
and education levels, and had lower access to BC screening centers as compared to women from 
the SEER-Medicare regions, the likelihood of being diagnosed with an earlier stage BC was 
higher for WV women who were persistent with mammography screening (AOR=4.18) as 
compared to women belonging to the SEER-Medicare cohort (AOR=1.44).  This indicates that 
enabling factors and external healthcare environmental factors had no negative impact on 
persistence with mammography screening in WV women diagnosed with BC, and they were 
diagnosed at earlier stages when the treatments are usually less aggressive, and survival is 
significantly better.  Among all the independent variables controlled in the model, only 
persistence with mammography screening was significantly associated with an earlier stage of 
disease in elderly WV women which indicates that persistence with mammography screening is 
extremely beneficial in these women to get diagnosed at an earlier stage of BC.  However, for 
the SEER-Medicare cohort, along with persistence with mammography screening, enabling 
factor such as higher census tract household income and healthcare use in terms of higher PCP 
visits significantly increased the likelihood of earlier representation of BC.  This indicates that 
women who have higher PCP visits are more likely to be consulted for healthy preventive 
behaviors such as mammography screening, and are more likely to get screening at regular 
intervals thereby being able to get diagnosed at an earlier stage of BC.   
When controlled for the type of setting (WV-Medicare vs SEER-Medicare) along with 
persistence with mammography screening and other independent variables, WV-Medicare cohort 
was more likely to be diagnosed at an earlier stage BC as compared to the SEER-Medicare 
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sample, but the association was not significant.  This indicates that elderly women in WV are 
equally likely to be diagnosed at an early stage BC as women in the SEER-Medicare sample.   
A major strength of this study is it helps in understanding the benefits of persistence with 
mammography screening for elderly women age 70 and above in a rural setting such as WV and 
how it differs from the national estimates obtained from the SEER-Medicare regions.  Utilization 
of the recently published algorithm with very high sensitivity (99.7%) and high predictive value 
(97.4%) to identify the screening mammograms from the Medicare claims files 
42
 may have 
improved the precision of the estimates and hence must also be considered a major strength of 
the study.  Though it is very crucial in appropriately distinguishing screening from diagnostic 
mammograms when evaluating screening utilization from claims-based data 
48
, difficulty in this 
distinction has been reported as a major limitation by several previous studies which have 




There are several limitations worth noting when interpreting the results of this study.  
Some of the study women may have been recipients of free screening mammograms which will 
not be captured in the Medicare data and hence may underestimate persistence with 
mammography screening.  However, this may not be considered a major limitation as Medicare 
is the primary health insurer for all of the older adult population.  Since the study utilized cancer 
registries-Medicare linked databases, certain patient characteristics such as annual household 
income, education level, access to total of BC screening centers at patient level are not available 
and hence census tract information for these variables has been utilized 
58
.  The findings of the 
study are generalizable only to elderly women age 70 and above, and to other rural areas having 




 The findings of the study indicate that persistence with mammography screening is 
significantly associated with earlier stage at BC diagnosis in elderly women in WV, and the 
likelihood of earlier representation of disease was similar in WV as compared to the national 







1. American Cancer Society. Breast Cancer Facts and Figures 2013-2014. Atlanta, GA. 
http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-040951.pdf. 
Updated 2014. Accessed 02/19, 2014. 
2. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 
(Vintage 2009 populations), National Cancer Institute. Bethesda, MD. Based on November 2011 
SEER data submission. http://seer.cancer.gov/csr/1975_2009_pops09/. Updated April 2012. 
Accessed 02/19, 2014. 
3. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. US 
National Institutes of Health, National Cancer Institute, Bethesda, MD 2008. 
4. Hillner BE, Penberthy L, Desch CE, McDonald MK, Smith TJ, Retchin SM. Variation in 
staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat. 
1996;40(1):75-86. 
5. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: An update for the U.S. 
preventive services task force. Ann Intern Med. 2009;151(10):727-737. 
6. Tabar L, Dean PB. Mammography and breast cancer: The new era. Int J Gynaecol Obstet. 
2003;82(3):319-326. 
7. Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N 
Engl J Med. 2003;348(17):1672-1680.  
8. Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography 
effective in elderly women? Am J Med. 2000;108(2):112-119. 
9. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term 
effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet. 
2002;359(9310):909-919.  
10. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service 
screening with mammography for women ages 40 to 49 years: Evaluation of the Swedish 
mammography screening in young women (SCRY) cohort. Cancer. 2011;117(4):714-722.  
11. Norman SA, Localio AR, Zhou L, et al. Benefit of screening mammography in reducing the 
rate of late-stage breast cancer diagnoses (United States). Cancer Causes Control. 
2006;17(7):921-929.  
12. American Cancer Society. Breast Cancer Facts and Figures 2012, Atlanta, Georgia. 
http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf. Updated 2012. 
Accessed 02/19, 2014. 
42 
 
13. US Preventive Services Task Force. Screening for breast cancer: U.S. preventive services 
task force recommendation statement. Ann Intern Med. 2009;151(10):716-726, W-236. 
14. Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 
2014: A review of current American Cancer Society guidelines and current issues in cancer 
screening. CA Cancer J Clin. 2014;64(1):30-51.  
15. U.S. Census Bureau. Persons 25 years old and over with a bachelor’s degree or more, 2008. 
Washington, DC: U.S. Census Bureau. 
http://www.census.gov/compendia/statab/2010/ranks/rank19.html. Updated 2010. Accessed 
02/24, 2014. 
16. U.S. Census Bureau. Persons below the poverty level, 2008. Washington, DC: U.S. Census 
Bureau. http://www.census.gov/compendia/statab/2010/ranks/rank34.html. Updated 2010. 
Accessed 02/24, 2014. 
17. Kaiser State Health Facts. Percent of adults who smoke by sex, 2008. Menlo park, CA: 
Kaiser Family Foundation. http://www.statehealthfacts.org. Updated 2008. Accessed 02/24, 
2014. 
18. Kaiser State Health Facts. Overweight and obesity rates for adults by sex, 2009. Menlo Park, 
CA: Kaiser Family Foundation. http://www.statehealthfacts.org. Updated 2009. Accessed 02/24, 
2014. 
19. Wingo PA, Tucker TC, Jamison PM, et al. Cancer in Appalachia, 2001-2003. Cancer. 
2008;112(1):181-192. 
20. Lengerich EJ, Chase GA, Beiler J, Darnell M. Increased risk of unknown stage cancer from 
residence in a rural area: Health disparities with poverty and minority status. Hershey, PA: 
Pennsylvania State University and the Penn State Cancer Institute, Department of Health 
Evaluation Sciences. 2006. 
21. State Cancer Profiles. Incidence and Mortality rate reports for West Virginia by county, 
2010. Bethesda, MD:  National Cancer Institute. http://statecancerprofiles.cancer.gov/. Updated 
2010. Accessed 02/24, 2014. 
22. United States Cancer Statistics. Rankings by State: 2006, male and female, all cancer sites 
combined. Atlanta, GA: Centers for Disease Control and Prevention (CDC). 
http://apps.nccd.cdc.gov/uscs/. Updated 2010. Accessed 02/24, 2014. 
23. United States Cancer Statistics. State vs. National rates: 2006, female, West Virginia. 
Atlanta, GA: Centers for Disease Control and Prevention (CDC). http://apps.nccd.cdc.gov/uscs/. 
Updated 2010. Accessed 02/24, 2014. 
24. Khanna R, Bhanegaonkar A, Colsher P, Madhavan SS, Halverson J. Breast cancer screening, 
incidence, and mortality in West Virginia. W V Med J. 2009;105 Spec No:24-32. 
43 
 
25. United States Cancer Statistics: 1999-2004 Incidence WONDER on-line database. United 
States Department of Health and Human Services, Centers for Disease Control and Prevention 
and National Cancer Institute. http://wonder.cdc.gov/cancer-v2004.html. Updated 2010. 
Accessed 02/24, 2014. 
26. United Health Foundation. American’s health rankings-2008 edition. 
http://www.americashealthrankings.org/2008/results.html. Updated 2008. Accessed 02/24, 2014. 
27. Centers for Disease Control and Prevention (CDC). State Cancer Profiles, 2008. 
http://statecancerprofiles.cancer.gov/. Updated 2008. Accessed 02/24, 2014. 
28. Centers for Disease Control and Prevention, National Center for Health Statistics. 
Compressed mortality file 1999-2005. CDC WONDER. http://wonder.cdc.gov/cmf-icd10.html. 
Updated 2010. Accessed 02/24, 2014. 
29. SEER State Cancer Profiles 2009. 
http://statecancerprofiles.cancer.gov/map/map.withimage.php?00&157&055&00&2&01&1&1&
6&0#map. Updated 2009. Accessed 02/19, 2014. 
30. SEER State Cancer Profiles 2009. 
http://statecancerprofiles.cancer.gov/map/map.withimage.php?00&157&055&00&2&02&1&1&
6&0#map. Updated 2009. Accessed 02/19, 2014. 
31. Hall HI, Uhler RJ, Coughlin SS, Miller DS. Breast and cervical cancer screening among 
Appalachian women. Cancer Epidemiol Biomarkers Prev. 2002;11(1):137-142. 
32. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for 
individualized decision making. JAMA. 2001;285(21):2750-2756. 
33. Caplan LS, Haynes SG. Breast cancer screening in older women. Public Health Rev. 
1996;24(2):193-204. 
34. MMWR Morb Mortal Wkly Report. Use of mammography services by women aged > or = 
65 years enrolled in Medicare-United States, 1991-1993. 1995;44;777-781. 
35. Day NE. Quantitative approaches to the evaluation of screening programs. World J Surg. 
1989;13(1):3-8. 
36. Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of 
differences in breast cancer survival across Europe. Int J Cancer. 2003;106(3):416-422.  
37. McCarthy EP, Burns RB, Freund KM, et al. Mammography use, breast cancer stage at 
diagnosis, and survival among older women. J Am Geriatr Soc. 2000;48(10):1226-1233. 
44 
 
38. Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is 
associated with elimination of age-related disparities in size and stage of breast cancer at 
diagnosis. Ann Intern Med. 2002;137(10):783-790. 
39. Badgwell BD, Giordano SH, Duan ZZ, et al. Mammography before diagnosis among women 
age 80 years and older with breast cancer. J Clin Oncol. 2008;26(15):2482-2488.  
40. Galit W, Green MS, Lital KB. Routine screening mammography in women older than 74 
years: A review of the available data. Maturitas. 2007;57(2):109-119.  
41. Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring 
breast, colorectal, and prostate cancer screening with Medicare claims data. Med Care. 
2002;40(8 Suppl):IV-36-42.  
42. Fenton JJ, Zhu W, Balch S, Smith-Bindman R, Fishman P, Hubbard RA. Distinguishing 
screening from diagnostic mammograms using Medicare claims data. Med Care. 2014 
July;52(7):e44-e51.  
43. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare 
data: Content, research applications, and generalizability to the United States elderly population. 
Med Care. 2002;40(8 Suppl):IV-3-18.  
44. Cancer Incidence in West Virginia, 1993-2009, West Virginia Cancer Registry, Charleston 
WV, 2012. 
45. Nadpara PA, Madhavan SS. Linking Medicare, Medicaid, and cancer registry data to study 
the burden of cancers in West Virginia. Medicare and Medicaid Research Review. 
2012;2(4):02/25/2014. 
46. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. (eds). SEER summary staging 
manual-2000: Codes and coding instructions, National Cancer Institute, NIH pub. no. 01-4969. . 
2001. 
47. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer 
incidence. N Engl J Med. 2012;367(21):1998-2005.  
48. Randolph WM, Mahnken JD, Goodwin JS, Freeman JL. Using Medicare data to estimate the 
prevalence of breast cancer screening in older women: Comparison of different methods to 
identify screening mammograms. Health Serv Res. 2002;37(6):1643-1657. 
49. Gierisch JM, Reiter PL, Rimer BK, Brewer NT. Standard definitions of adherence for 
infrequent yet repeated health behaviors. Am J Health Behav. 2010;34(6):669-679.  
50. Braithwaite D, Zhu W, Hubbard RA, et al. Screening outcomes in older US women 
undergoing multiple mammograms in community practice: Does interval, age, or comorbidity 
45 
 
score affect tumor characteristics or false positive rates? J Natl Cancer Inst. 2013;105(5):334-
341.  
51. Andersen RM. Revisiting the behavioral model and access to medical care: Does it matter? J 
Health Soc Behav. 1995;36(1):1-10. 
52. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in 
the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95-124. 
53. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index 
using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267. 
54. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 
1987;40(5):373-383. 
55. National Cancer Institute: SEER-Medicare: Calculation of comorbidity weights. . 
http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Updated 2013. 
Accessed 02/25, 2014. 
56. Yu X, McBean AM, Virnig BA. Physician visits, patient comorbidities, and mammography 
use among elderly colorectal cancer survivors. J Cancer Surviv. 2007;1(4):275-282.  
57. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. John Wiley & Sons, Inc.; 
2000. 
58. Krieger N. Overcoming the absence of socioeconomic data in medical records: Validation 

























*Key Independent Variable 
 








Health Care Use Population Characteristics 













































































Figure 2.2:  WV-Medicare Cohort by Persistence with Mammography Screening 
 















Figure 2.4:  Stage at Breast Cancer Diagnosis by Persistence with Mammography 




Figure 2.5:  Stage at Breast Cancer Diagnosis by Persistence with Mammography 



















































Description of the Study Cohorts by Persistence with Mammography Screening 
2007 
Variables WV-Medicare (N=221) SEER-Medicare (N=7,945) 
    
Non-
Persistent % Persistent % Sig 
Non-
Persistent % Persistent % Sig 












  Stage at BC Diagnosis 
    
*** 
    
*** 
 
Early 75      69.4 100 88.5 
 
2653 61.1 3000 83.2 
 
 
Late 33 30.6 13 11.5 
 
1688 38.9 604 16.8 
 Age at Diagnosis 
    
* 
    
*** 
 
70-74 34 31.5 38 33.6 
 
1183 27.3 1325 36.8 
 
 
75-79 23 21.3 38 33.6 
 
1141 26.3 1094 30.4 
 
 
80,+ 51 47.2 37 32.7 
 
2017 46.5 1185 32.9 
 Race/Ethnicity 
         
*** 
 
White NA NA NA NA 
 
3753 86.5 3242 90.0 
 
 
Other NA NA NA NA 
 
588 13.5 362 10.0 
 Location of Residence 
         
 
Metro 65 60.2 55 48.7 
 
3609 83.1 3018 83.7 
 
 
Urban 23 21.3 40 35.4 
 
633 14.6 530 14.7 
 
 
Rural 20 18.5 18 15.9 
 
99 2.3 56 1.6 
 Census Tract Household Income 
        
*** 
 
LE $35,000 95 88.0 102 90.3 
 
1200 27.6 783 21.7 
 
 
GT $35,000 13 12.0 11 9.7 
 
3141 72.4 2821 78.3 
 Census Tract Education 
        
*** 
 
LT 15% pop. with 
CE 44 40.7 57 50.4 
 
1462 33.7 943 26.2 
 
 
GE 15% pop. 
with CE 64 59.3 56 49.6 
 
2879 66.3 2661 73.8 
 Comorbidity 
         
*** 
 
0 45 41.7 60 53.1 
 
2143 49.4 1959 54.4 
 
 
1 33 30.6 30 26.5 
 
1235 28.4 1048 29.1 
 
 
2,+ 30 27.8 23 20.4 
 
963 22.2 597 16.6 
 PCP visits 
         
*** 
 
High 54 50.0 55 48.7 
 
2275 52.4 1650 45.8 
 
 
Low 54 50.0 58 51.3 
 
2066 47.6 1954 54.2 
 Total BC Screening Centers 









                         
Note: Based on 221 elderly WV-Medicare women and 7,945 elderly SEER-Medicare women, age 70 and above diagnosed with 
primary incident breast cancer in 2007.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary 
Care Physicians, BC, Breast Cancer; pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater 
than or equal to; CE, College education; Sig, Significance; NA, Not Applicable. For WV-Medicare cohort, χ2 test for 
race/ethnicity variable was not performed due to 0 sample size in one of the persistent groups. Asterisks represent statistically 
significant group differences based on χ2 tests and t-tests separately for two study cohorts: ***P<0.001; **001<=P<.01; 
*.01<=P<.05.   















Association between Persistence with Mammography Screening and Stage at Breast Cancer Diagnosis, 
Separately for WV-Medicare and SEER-Medicare 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions 
2007 
Variables   WV-Medicare (N=221) SEER-Medicare (N=7,945) 
    AOR 95% CI Sig AOR 95% CI Sig 
Persistence with Mammography Screening 
     
 





  Age at Diagnosis 
















       
 





Other NA NA 
 
1 
  Location of Residence 












Rural 1.00 [0.31,3.15] 
 
1 [0.72,1.39] 
 Census Tract Household Income 
      
 





GT $35,000 0.77 [0.21,2.85] 
 
1.19 [1.04,1.35] ** 
Census Tract Education 
      
 






GE 15% pop. with 
















2,+ 0.89 [0.36,2.24] 
 
1.04 [0.92,1.18] 
 PCP visits 
       
 
High 1.24 [0.60,2.56] 
 





  Total BC Screening Centers 0.85 [0.52,1.38] 
 
1.00 [1.00,1.01] 
               
        Note: Based on 221 elderly WV-Medicare women and 7,945 elderly SEER-Medicare women, age 70 and 
above diagnosed with primary incident breast cancer in 2007.  WV, West Virginia; SEER, Surveillance, 
Epidemiology, and End Results; PCP, Primary Care Physicians, BC, Breast Cancer; CE, College Education; 
pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; 
AOR, Adjusted odds ratio; CI, Confidence Interval; Sig, Significance; NA, Not Applicable. The regressions 
also include intercept terms and parameter estimates for other variable controlled are not presented. "Late 
Stage at Breast Cancer Diagnosis" is the reference group for the dependent variable for both the study 
cohorts. For WV-Medicare cohort, logistic regression did not include race/ethnicity as one of the controlled 
variables due to 0 sample size in one of the persistent groups.  Asterisks represent statistically significant 
group differences compared with the reference group: ***P<0.001; **001<=P<.01; *.01<=P<.05.   














Description of WV-Medicare and SEER-Medicare (randomly selected non-Hispanic white SEER-
Medicare) cohorts 
2007 




(N=708)   
    N % N % Sig 
       Stage at BC Diagnosis 
     
 
Early 175 79.2 514 72.6 
 
 
Late 46 20.8 194 27.4 
 Persistence with Mammography Screening 
     
 
Persistent 113 51.1 339 47.9 
 
 
Non-Persistent 108 48.9 369 52.1 
        Age at Diagnosis   
  
 
70-74 72 32.6 242 34.2 
 
 
75-79 61 27.6 179 25.3 
 
 
80,+ 88 39.8 287 40.5 
 Location of Residence 
    
*** 
 
Metro 120 54.3 580 81.9 
 
 
Urban 63 28.5 120 16.9 
 
 
Rural 38 17.2 8 1.1 
 Census Tract Household Income 
   
*** 
 
LE $35,000 197 89.1 147 20.8 
 
 
GT $35,000 24 10.9 561 79.2 
 Census Tract Education 
    
*** 
 
LT 15% pop. with CE 101 45.7 192 27.1 
 
 
GE 15% pop. with CE 120 54.3 516 72.9 
 Comorbidity 
      
 
0 105 47.5 374 52.8 
 
 
1 63 28.5 193 27.3 
 
 
2,+ 53 24.0 141 19.9 
 PCP visits 
      
 
High 112 50.7 325 45.9 
 
 
Low 109 49.3 383 54.1 
 Total BC Screening Centers 







              
       Note: Based on 221 elderly WV-Medicare women and randomly selected non-Hispanic white 708 
elderly SEER-Medicare women, age 70 and above diagnosed with primary incident breast cancer in 
2007.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary Care 
Physicians, BC, Breast Cancer; pop., population; CE, College Education; LE, Less than or equal to; GT, 
Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent 
statistically significant group differences based on χ2 tests and t-tests: ***P<0.001; **001<=P<.01; 
*.01<=P<.05.   















Differences in Stage at Breast Cancer Diagnosis between Study Cohorts 
In a Multivariate Framework 
Adjusted Odds Ratio and 95% Confidence Intervals from Logistic Regression 
2007 
Variables   Early Stage at Diagnosis 
    AOR 95% CI Sig 
          
     Type of Setting 
   
 




  Persistence with Mammography Screening 
   
 
Persistent 2.87 [2.08,3.97] *** 
 
Non-Persistent 1 
  Age at Diagnosis 





75-79 0.63 [0.42,0.93] * 
 
80,+ 0.94 [0.65,1.36] 
 Location of Residence 





Urban 0.99 [0.65,1.50] 
 
 
Rural 1.12 [0.51,2.47] 
 Census Tract Household Income 
  
 
LE $35,000 1 
  
 
GT $35,000 1.05 [0.66,1.67] 
 Census Tract Education 
   
 
LT 15% pop. with CE 1 
  
 
GE 15% pop. with CE 1.60 [1.07,2.40] * 
Comorbidity 





1 0.82 [0.57,1.18] 
 
 
2,+ 1.06 [0.70,1.61] 
 PCP visits 
    
 




  Total BC Screening Centers 1.00 [0.98,1.02] 
           
     Note: Based on 221 elderly WV women and 708 randomly selected non-Hispanic elderly women from 
SEER-Medicare, age 70 and above diagnosed with primary incident breast cancer in 2007.  WV, West 
Virginia; SEER, Surveillance, Epidemiology, and End Results; PCP, Primary Care Physicians, BC, 
Breast Cancer; CE, College Education; pop., population; LE, Less than or equal to; GT, Greater than; 
LT, Less than; GE, Greater than or equal to; AOR, Adjusted odds ratio; CI, Confidence Interval; Sig, 
Significance. The regressions also include intercept terms and parameter estimates for other variable 
controlled are not presented. "Late Stage at Breast Cancer Diagnosis" is the reference group for the 
dependent variable.  Asterisks represent statistically significant group differences compared with the 
reference group: ***P<0.001; **001<=P<.01 ; *.01<=P<.05.   




























































TIMELY DIAGNOSIS AND TREATMENT OF BREAST CANCER IN ELDERLY 
WOMEN 
INTRODUCTION 
Breast Cancer  
 
Breast cancer (BC) is the most common occurring cancer in women and is the second 
leading cause of cancer death in women in the United States (US).  As per the Surveillance, 
Epidemiology and End Results (SEER) statistics for 2005-2009, the overall incidence of BC was 
82.97 per 100,000 women in those below 65 years of age and was 421.30 per 100,000 women in 
those age 65 and above 
1
 and the overall mortality from BC was 11.15 per 100,000 women in 
those below 65 years of age and was 98.64 per 100,000 women in those age 65 and above 
1
.  
Moreover, older women age 65 and above have a greater burden of BC as cancer in these women 
may be found at more advanced stages and with larger tumor sizes thereby leading to poorer 
survival 
2
.  However, BC has 5-years survival of 88.5% in elderly women age 65 and above 
which is only a little lower as compared to 89.7% for women below 65 years of age 
3
. 
Timely Diagnosis and Treatment of Breast Cancer in Elderly Women 
 BC is a major and complex health issue among women and the second cause of cancer-
related deaths among women in the US, as such, measuring quality of care delivered to BC 
patients is challenging.  Timeliness of care, i.e., rapid diagnosis after noticing abnormality in the 
breast and rapid initiation of treatment after diagnosis, is one of the key components of high-
quality cancer treatment.  Determining timeliness of care provided to BC patients is extremely 
important as both patients and referring care providers expect rapid access to care for breast 
problems 
4,5
.  Also, emotional distress may occur during the wait time for the patient’s diagnostic 
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evaluation and subsequent treatment 
6-8
.  Most research in this area has demonstrated a possible 




 To our knowledge, despite the widely accepted benefit of timely care in BC patients, US-
based agencies such as the National Initiative for Cancer Care Quality, National Comprehensive 
Cancer Network Quality, American Society of Clinical Oncology, National Quality Forum are 
yet to define guidelines for an appropriate time frame from presentation of abnormality to 
confirmed diagnosis and from diagnosis to the initiation of the treatment 
10
.  As per a quality 
review of the timeliness of BC diagnosis and treatment 
11
, the European Society of Breast Cancer 
Specialists (EUSOMA) has published professional opinion-based guidelines on time intervals 
between various events from presentation of abnormality to diagnosis of BC 
12,13
.  Moreover, the 
National Health Service of United Kingdom has published professional opinion-based guidelines 
on appropriate time interval from BC diagnosis to the initiation of the treatment 
14
.  The US-
based National Initiative of Cancer Care Quality (NICCQ) has suggested time intervals for few 
events which occur between presentation of abnormality to initiation of treatment, however it 
does not define the appropriate time from presentation of abnormality to confirmed diagnosis 
and from diagnosis to the initiation of the treatment 
15
.   
Despite numerous studies about timeliness of BC care have been conducted in the last 
decade in the US 
16-24
, no consensus exists regarding the time intervals for diagnosis and 
treatment delays.  Among the studies about delay in diagnosis, only three studies included 
women age 65 and above in their analyses 
16,19,20
.  One study did not assess the effect of 
important clinical covariates such as tumor size, grade of tumor, ER- and PR-status, socio-
economic variables such as income and education, and access factors, which affect timely 
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diagnosis and care 
20
.  While other two studies were conducted in a smaller geographic location 
which may affect the generalizability of the findings to other populations 
16,19
.  Among studies 
about delay of treatment, only four studies included women age 65 years and above in their 
analyses 
21-24
.  One study restricted women till 72 years of age and did not adjust for any clinical 
covariates which affect treatment delays 
21
.  Another study was limited to North Carolina-
Medicaid population only which may affect the generalizability of the findings to the other 
populations 
22
.  Only two studies were conducted using SEER-Medicare dataset of which one 
study did not include patients with distant or stage IV disease and did not adjust for clinical 
covariates and access factors in the analyses 
24
, and the other study reported treatment delay in 
terms of months (whole numbers), which was not consistent with any of the studies estimating 
delay in care 
23
.  Finally, none of the above studies followed the published opinion-based 
EUSOMA, National Health Service of United Kingdom or any guidelines to define timeliness of 
diagnosis and treatment in women with BC.   
As older women age 65 years and above have higher BC incidence and mortality and are 
more likely to have advanced stage disease with larger tumors 
1,2
, it is highly likely that 
diagnosis delay and/or treatment delay may negatively affect the prognosis of the disease and 
hence the survival.  Hence, it is extremely important to determine timeliness of care based on the 
published opinion-based guidelines among elderly BC patients in the US.   
WV is the only state that lies entirely in Appalachia, a region which is a predominantly 
rural and medically underserved in the United States characterized by high poverty rates, low 
levels of education, aging population, high rates of chronic disease, and poor health behaviors 
25-
28
.   With lower incidence of BC among WV women age 65 and older (372.8 per 100,000 vs. 





compared to the national estimates, and with higher rates of advanced and unstaged BC in these 
women 
31-35
, it is likely that timeliness of care may be one of the significant contributors to these 
disparities.  Therefore, a study comparing the timeliness of care among elderly BC patients from 
WV to the national estimates may help understand these disparities.   
Hence, the purpose of the study is to determine timeliness of BC care based on published 
recommendations and its effect on survival in elderly women with BC among WV Medicare fee-
for-service (FFS) women beneficiaries and compare it with the national estimates derived from 
SEER-Medicare data, and to determine the factors associated with timeliness of BC care in WV 
women and compare it with the national estimates, after controlling for predisposing factors 
(age, race), enabling factors (median household income, education level), need-related factors 
(stage at diagnosis, grade of tumor, estrogen-receptor (ER) status, co-occurring chronic 
conditions), factors associated with healthcare use (number of primary care physicians (PCP) 
visits in year prior to BC diagnosis, type of initial cancer-related treatment) and external 
healthcare environmental factors (location of residence and number of hospitals offering 




West Virginia Cancer Registry-Medicare-Area Resource File linked dataset 
 
Established in 1993 by the West Virginia Department of Health and Human Resources, 
the West Virginia Cancer Registry (WVCR) provides information on cancer incidence and 
mortality in the state 
36
.  The registry provides information on clinical characteristics of cancer 
such as primary cancer site, tumor grade, date and stage of diagnosis, date and cause of 
mortality, and demographic data on age, gender, race, and zip code.  In the full compliance with 
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the WVU Institutional Review Board and HIPPA requirements, the de-identified linked WVCR-
Medicare dataset was established at West Virginia University which provided information about 
WV individuals who are age ≥ 65 years and diagnosed with cancer between the January 1, 2002 
and December 31, 2007 
37
.  The Social security numbers (SSN) for individuals in WVCR were 
then provided to the CMS by the WVCR, using which the CMS identified the corresponding 
Health Insurance Claim (HIC) number.   A “crosswalk” file created using the HIC allowed for 
linkage across the WVCR and the Medicare for extracting information on these individuals as 
Medicare beneficiaries.  Individuals with a missing SSN were excluded from the linkage.  To 
extract the county level information on the availability of healthcare facilities, and 
socioeconomic characteristics of the region’s population, the Area Resource File (ARF) was 
linked to the WVCR-Medicare dataset using the state and county FIPS codes for each 
beneficiary. 
SEER-Medicare-Area Resource File linked dataset 
The SEER-Medicare linked dataset provides important data useful for population-level 
cancer-related epidemiologic and health outcomes studies.  The SEER-Medicare program 
collects information on newly diagnosed cases of cancer from 17 population-based tumor 
registries which ultimately collect information from hospitals, outpatient clinics, laboratories, 
private practitioners, laboratories, hospices, autopsy reports and death certificates and it 
represents 26% of the US population.  Patient Entitlement and Diagnosis Summary File (PEDSF) 
is a customized file which contains one record per person for individuals in the SEER part of the 
SEER-Medicare database who have been matched with Medicare enrollment records.  PEDSF 
provides diagnostic information for up to 10 diagnosed cancer cases (including date of cancer 
diagnosis, cancer sub-site, cancer stage at diagnosis), and information on the first course of 
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cancer related treatment (surgery and radiation provided in the first 4 months after diagnosis) for 
each individual.  Additionally it includes information on the median household income and 
education level for each individual based on their census tract and zip code data.  
The Medicare files of the SEER-Medicare linked dataset provide data about health care 
utilization inpatient, outpatient, physician, home health, and hospice care by individuals age 65 
and above who are enrolled in the Medicare program.  These files have information about dates 
of healthcare service and codes for specific diagnosis and procedures using the International 
Classification of Disease, Ninth Edition (ICD-9) codes or Common Procedure Terminology 
codes.  The linkage process of the SEER data with the Medicare data is described elsewhere 
38
.  
The Area Resource File (ARF) was linked to the SEER-Medicare dataset using the state and 
county Federal Information Processing Standards (FIPS) code for each beneficiary to extract the 
county level information on the availability of healthcare facilities and healthcare providers. 
Study Design 
 This study utilized a retrospective observational cohort design to assess time to diagnosis 
and time to treatment and its effect on chances of being alive among Medicare FFS beneficiaries 
diagnosed with BC. 
Study Cohorts 
The two cohorts for this study consisted of women from WVCR-Medicare-ARF linked 
dataset and SEER-Medicare-ARF linked dataset, age 66 and older at the first primary 
pathologically confirmed diagnosis of incident BC from January 1, 2003 to December 31, 2006.  
These women were required to be continuously enrolled in Medicare parts A and B at least 12 
months prior to the BC diagnosis to identify comorbidities and timeliness of care from the initial 
consultation to BC diagnosis, and till the follow-up period of 12 months after BC diagnosis to 
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determine timeliness of care from diagnosis to treatment.  Women who died during the study 
period and who were enrolled in health maintenance organizations (HMOs) at any time during 
the study period were excluded from the study.  Also, women with any previous cancer 
diagnosis, with unknown or missing stage of BC, and who were diagnosed through death 
certificate or autopsy were excluded from the study.  To determine the effect of timeliness of 
care on the probability of being alive, women diagnosed with first primary pathologically 
confirmed incident BC from January 1, 2003 to December 31, 2004 and who followed all the 
inclusion and exclusion criteria as described above were identified from both the datasets and 
were followed for three years.  BC diagnosis codes were based on the primary site and 
International Classification of Diseases, 9th edition Clinical Modification (ICD-9-CM) codes 
174.xx, 233.0x, 238.3x, and 239.3x. 
The WVCR-Medicare-ARF linked dataset identified 2,814 women diagnosed with BC 
from January 1, 2003 to December 31, 2006.  The following women were excluded from the 
final study population: 152 women who were below 66 years at diagnosis, 527 women with any 
previous cancer diagnosis, 24 women who were diagnosed with BC during death or autopsy, 246 
women with unknown or missing BC stage, 245 women who were not continuously enrolled in 
Medicare parts A and B in the 12 months before and 12 months after diagnosis, and 232 women 
who were members of a HMO any time during the study period.  Thus, a final sample of 1,388 
women who had claims for breast biopsy was included in the final analyses. 
The SEER-Medicare-ARF linked dataset had 112,719 women diagnosed with BC from 
January 1, 2003 to December 31, 2006.  The following women were excluded from the final 
study population: 45,198 women who were below 66 years at diagnosis, 3,385 women with any 
previous cancer diagnosis, 815 women who were diagnosed with BC during death or autopsy, 
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1,947 women with unknown or missing BC stage, 5,714 women who were not continuously 
enrolled in Medicare parts A and B in 12 months before and 12 months after diagnosis, 14,671 
women who were members of a HMO any time during the study period, and 7 women from all 
the remaining women who died during the 12 months after BC diagnosis.  From the remaining 
40,982 women, 4,706 women did not have claims for breast biopsy which were used to ascertain 
biopsy-proved diagnosis and hence were removed from the analyses.  Thus, a final sample of 
36,276 women was included in the final analyses. 
Measures 
Timely Care Intervals 
Based on previous studies 
16,17
, two intervals were created for both the study cohorts: 
timely diagnosis, timely treatment and timely clinical care.   
Timely Diagnosis:  Timely diagnosis was defined as the period (in days) between the initial 
consultation for abnormality and biopsy-proved BC diagnosis as per the published opinion-based 
guidelines.  Breast biopsies (fine-needle aspiration, core biopsy, incision, or excision) were 
identified using Current Procedural Terminology (CPT) and International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes.  The initial 
consultation date for abnormality was defined as the date of a consultation for breast symptoms 
or date of diagnostic mammography or diagnostic magnetic resonance imaging (MRI) or 
diagnostic ultrasonography.  Breast symptoms were identified using International Classification 
of Diseases, Ninth Revision, Clinical Modification diagnostic codes 611.7x and 611.9 occurring 
within one year before the breast biopsy proved diagnosis date.  Diagnostic mammograms were 
identified using CPT codes 76090, 76091, 77055, 77056, G0204, G0206.   Diagnostic MRI was 
identified using CPT codes 76093, 76094, 77058, 77059, C8903-C8908 and diagnostic 
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ultrasonography was identified using CPT code 76645.  According to the published guidelines of 
the EUSOMA on quality assurance in the diagnosis of breast disease 
12,13
, the number of days 
from abnormality in the form of breast symptom or diagnostic procedure to the confirmed BC 
diagnosis range from 21 days (3 weeks) to 35 days (5 weeks).  This range is calculated based on 
the guideline recommended time interval for each event and the typical sequence of events 
leading to diagnosis of BC depending on the type of abnormality.  Hence, diagnosis delay was 
categorized into two groups based on the number of days from initial consultation for 
abnormality to biopsy-proved BC diagnosis (timely diagnosis - 35 days or less, and delayed 
diagnosis - greater than 35 days). 
Timely Treatment:  Timely treatment was defined as the period (in days) between biopsy-proven 
BC diagnosis and the initiation of treatment as per the published opinion-based guidelines.  
Treatment was defined as definitive surgery, neoadjuvant chemotherapy or radiation, whichever 
came first.  The use of prescription drug was not included in the analysis as data pertaining to 
prescription drugs was not available for these study cohorts.  According to the only published BC 
care guidelines by National Health Service of United Kingdom on timeliness to BC treatment, 
the initiation of treatment should occur within less than or equal to 4 weeks (28 days) after BC 
diagnosis 
14
.  Based on this guideline, timely treatment was categorized into two groups based on 
number of days from biopsy-proved BC diagnosis to initiation of the treatment (timely treatment 
- 28 days or less, and delayed treatment - greater than 28 days). 
Independent Variables:  To identify the factors associated with timely BC care in elderly 
Medicare FFS with first primary incident BC, the Andersen behavioral healthcare services 
utilization model was utilized 
39,40
.  Based on this model, the independent variables were grouped 
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into predisposing factors, enabling factors, need-related factors, healthcare use factors and 
external healthcare environmental factors (Figure 3.1). 
Predisposing factors included age at diagnosis (66-69, 70-74, 75-79, 80 and older), and 
race (white, other), and enabling factors included census tract median household income 
(=<$35,000; >$35,000), and census tract percentage of people age >= 25 years with at least 4 
years of college education (<15%, >=15%).  As individual level information on household 
income and education level are not available with both SEER-Medicare and WVCR-Medicare 
datasets, census tract information for these two variables was used.  Need-related factors 
consisted of clinical covariates such as stage at diagnosis (insitu, local, regional, distant), grade 
of tumor (well-differentiated, moderately differentiated, poorly differentiated, 
undifferentiated/unknown), estrogen-receptor status (positive, negative, borderline/unknown), 
tumor size (<1 cm, 1-2 cm, 2-3 cm, >3 cm), and comorbidity scores obtained from co-occurring 
chronic conditions during the 12 months prior to BC diagnosis identified from the Medicare files 
using the ICD-9-CM diagnosis codes.  As stage at BC diagnosis is considered as a predictor or 
outcome of delay and as chemotherapy treatment choices are determined by stage, and tumor 
size, grade of tumor, estrogen receptor status 
41
, these variables were included in the analyses.  
BC stage at diagnosis was determined according to the SEER Summary staging system that uses 
all information available in the medical record.  It is a combination of the most precise clinical 
and pathological documentation of the extent of disease 
42
.  Comorbidity scores were calculated 
using Charlson comorbidity index to account for possible misclassification using codes from 
physician claims with macros provided by the National Cancer Institute 
43-45
.  The comorbidity 
scores were categorized as 0 (no comorbidity), 1, 2+.  The number of primary care physicians 
(PCP) visits 12 months prior to BC diagnosis was included as a healthcare use factor in the 
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model and its median value was utilized to categorize as low or high.  External healthcare 
environmental factors included location of residence (metro, non-metro) and ARF-derived 
number of hospitals offering oncology-related services and number of hospitals offering BC 
screening and mammography services in the area of residence, both categorized as low or high 
based on their respective median values.   
Statistical Analyses 
Descriptive statistics and chi-square statistics were used to describe the characteristics 
and the significant differences in characteristics between the two study cohorts.  Unadjusted 
median time to diagnosis (in days) in women who had any initial consultation and median time 
to treatment (in days) in women who had any BC treatment, with their respective 25% and 75% 
inter quartile range (IQR) were estimated for both the study cohorts.  These time periods (median 
days with IQR) were also estimated for all the groups within each independent variable.  In 
addition, a non-parametric test, Kruskal-Wallis test, was performed to assess statistical 
significant differences in time period for diagnosis and treatment within each group.  Bar charts 
were used to exhibit timely diagnosis and timely treatment based on published opinion-based 
recommendations for both the Medicare study cohorts.  Separate logistic regression models were 
used to characterize timely diagnosis and timely treatment based on published opinion-based 
recommendations for both the study populations to identify the predictors of timely care, after 
controlling for all the independent variables.  Logistic regressions were also conducted on timely 
diagnosis and timely treatment to determine significant differences in timely care between WV-
Medicare and SEER-Medicare cohorts.  In all models, “delayed care” for diagnosis and 
treatment were used as the reference group for the dependent variables.  Another set of logistic 
regressions to model the association between timely diagnosis and timely treatment and survival, 
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were performed to determine significant differences in survival between WV-Medicare and 
SEER-Medicare cohorts.  In these regressions, “death” was used as the reference group for the 
dependent variable.  From all the logistic regressions, the parameter estimates were transformed 
to odds ratios, and their corresponding 95% confidence intervals were examined.  The findings 
that were significant with p-values less than 0.05 levels are discussed.  All analyses were 
conducted within statistical analysis system software SAS 9.3 (SAS
®
 version 9.3, SAS Institute 
Inc., Cary, NC, USA). 
RESULTS 
Description of the Study Cohorts 
Table 3.1 describes the WV-Medicare and SEER-Medicare women age 66 and above, 
diagnosed with first primary incident BC in 2003-2006.  Twenty-five percent of women in WV 
cohort were age 80 and above as compared to 29% in SEER-Medicare.  Approximately 98% of 
the WV-Medicare women were white as compared to 89% in the SEER-Medicare cohort.  A 
higher proportion of WV-Medicare cohort had household income below $35,000 (91%), resided 
in areas with less than 15% population with some college education (51%), and resided in areas 
with lower number of hospitals with oncology services (60%) and BC screening centers (58%).  
However, a majority of SEER-Medicare women resided in metro areas (84%), had household 
income above $35,000 (75%), resided in areas with greater than 15% of population with some 
college education (70%), and resided in areas with lower number of hospitals with oncology 
services (56%) and BC screening centers (51%). 
Median Days for Diagnosis and Treatment for the Study Cohorts 
Table 3.2 describes median time period in days with IQR for diagnosis and treatment in 
the WV-Medicare and SEER-Medicare cohorts.  The median days from initial consultation for 
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abnormality to BC diagnosis was 26 (IQR=12-50 days) for the WV-Medicare cohort as 
compared to 20 (IQR=8 to 41 days) for the SEER-Medicare cohort.  The overall median days 
from BC diagnosis to any BC treatment was 8 (IQR=0-28 days) for the WV-Medicare cohort as 
compared to 15 (IQR=0-29 days) for the SEER-Medicare cohort.  Among women who had their 
first BC treatment as surgery, the median days from BC diagnosis to surgery was 0 (IQR=0-25 
days) for the WV-Medicare cohort as compared to 14 (IQR=0-29 days) for the SEER-Medicare 
cohort.  Women who had their first BC treatment as chemotherapy, the median days from BC 
diagnosis to chemotherapy was 20 (IQR=15-29 days) for the WV-Medicare cohort as compared 
to 25 (IQR=14-45 days) for the SEER-Medicare cohort.  However, women who had their first 
BC treatment as radiation therapy, the median days from BC diagnosis to radiation therapy was 
27 (IQR=16-48 days) for the WV-Medicare cohort as compared to 28 (IQR=15-49 days) for the 
SEER-Medicare cohort. 
Median Days for Type of Initial Treatment by Stage at Diagnosis for the Study Cohorts 
Table 3.3 describes median time period in days with IQR for type of initial treatment by 
stage at BC diagnosis in the WV-Medicare and SEER-Medicare cohorts.  The median days from 
BC diagnosis to surgery as the first treatment increased with advancing stage of tumor for the 
WV-Medicare cohort.  It was 0 days for insitu tumor and 10 days for distant tumor.  However, 
the median days from BC diagnosis to surgery as the first treatment did not vary much by stage 
at diagnosis for the SEER-Medicare cohort.  It was 11 days for insitu tumor and 14 days for 
distant tumor.  The median days from BC diagnosis to first treatment with chemotherapy ranged 
from 17 (distant tumor) to 178 (insitu tumor) for the WV-Medicare cohort.  While the median 
days from BC diagnosis to first treatment with chemotherapy were 21 for insitu, 29 for local, 25 
for regional and 24 for distant tumors for women in the SEER-Medicare cohort.  The median 
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days from BC diagnosis to radiation therapy as the first treatment were 31 for insitu, 27 for local, 
17 for regional and 25 for distant tumors for women in the WV-Medicare cohort.  However, the 
median days from BC diagnosis to radiation therapy as the first treatment were 28 for insitu, 30 
for local, 29 for regional and 13 for distant tumors for women in the SEER-Medicare cohort. 
Median Days for Diagnosis and Treatment within Independent Variables for the Study 
Cohorts 
Table 3.4 describes the significant differences in time period in median days with 
respective IQR for diagnosis and treatment within each independent variable for both the study 
cohorts.  For the WV-Medicare cohort, median time period for diagnosis was significantly 
different for stage at diagnosis, grade of tumor and tumor size. While for the SEER-Medicare 
cohort, median time period for diagnosis was significantly different for all the independent 
variables except census tract income and education.  For the WV-Medicare cohort, median time 
period for treatment was significantly different for age at diagnosis, census tract income, stage at 
diagnosis, ER status, and the number of hospitals with oncology services in the area of residence.  
However, for the SEER-Medicare cohort, median time period for treatment was significantly 
different for all the variables except mental health condition and number of hospitals with 
oncology services in the area of residence. 
Proportion of Study Cohorts Receiving Timely Diagnosis and Treatment as Per the 
Published Recommendations 
Figure 3.2 summarizes the proportion of the study cohorts who received timely BC 
diagnosis of BC as per the published opinion-based recommendations.  Approximately only 63% 
of women in the WV-Medicare cohort received timely diagnosis of BC as compared to 71% of 
the SEER-Medicare cohort.  Figure 3.3 summarizes the proportion of the study cohorts who 
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received timely treatment of BC as per the published opinion-based recommendations.  Seventy-
six percent of the WV-Medicare cohort received timely BC treatment as compared to 73% of the 
SEER-Medicare cohort.  
Factors Associated with Timely Diagnosis and Timely Treatment  
Table 3.5 describes the factors associated with timely diagnosis and timely treatment as 
per the published opinion-based recommendations for both the study cohorts.  For the WV-
Medicare cohort, higher census tract household income above $35,000 (AOR=3.33, 95% 
CI=1.41-7.83) and tumor size > 3 cm was significantly associated with timely diagnosis of BC.  
While for the SEER-Medicare cohort, age 80 and above, white race (AOR=1.21, 95% CI=1.12-
1.30), non-metro residence (AOR=1.30, 95% CI=1.20-1.40), higher census tract education 
(AOR=1.07, 95% CI=1.01-1.14), distant stage of BC, moderately (AOR=1.09, 95% CI=1.02-
1.16) and poorly (AOR=1.26, 95% CI=1.17-1.36) differentiated grade of tumor, tumor size > 3 
cm, no comorbidity and low PCP visits were significantly associated with timely diagnosis of 
BC.  Surprisingly, no factors were significantly associated with timely treatment of BC for the 
WV-Medicare cohort.  However, for the SEER-Medicare cohort, age 66 to 74 years, white race 
(AOR=1.36, 95% CI=1.26-1.47), non-metro residence (AOR=1.28, 95% CI=1.18-1.39), earlier 
stages of BC, tumor size < 3 cm, no comorbidity, high PCP visits (AOR=1.06, 95% CI=1.01-
1.12), and low hospitals with oncology services in the area of residence were significantly 
associated with timely treatment of BC.   
Differences in Timely Diagnosis and Treatment between Study Cohorts in a Multivariate 
Framework 
Table 3.6 summarizes the results for timely diagnosis and timely treatment, to identify 
any significant differences in timeliness between WV-Medicare and SEER-Medicare study 
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cohorts.  As compared to the SEER-Medicare cohort, the WV-Medicare cohort was significantly 
less likely to receive timely diagnosis of BC (AOR=0.76, 95% CI=0.64-0.90), but it was equally 
likely as the SEER-Medicare cohort to receive timely treatment of BC (AOR=1.00, 95% 
CI=0.83-1.23).   
Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and 
Timely Treatment in a Multivariate Framework 
Table 3.7 summarizes the results on probabilities of survival with receipt of timely 
clinical BC care, to identify any significant differences between WV-Medicare and SEER-
Medicare study cohorts.  As compared to the SEER-Medicare cohort, the WV-Medicare cohort 
was significantly more likely to be alive at the follow-up period of three years. 
DISCUSSION 
 In the Institute of Medicine’s report Crossing the Quality Chasm, six constructs of 
healthcare quality are defined 
46,47
, out of which timeliness of care is one of the most important 
aspects of measuring quality of cancer care 
48
.  Delays in diagnosis and treatment in BC patients 
lead to high emotional distress in patients 
6-8,49
, and also poor health outcomes in terms of 
compromised survival 
9
.  Previous studies which evaluated timeliness of BC care in elderly BC 
patients using nationally representative populations did not use any published recommendations 
to define timely BC care 
16-24
.  This is the first study to identify differences in timeliness of BC 
care (diagnosis, treatment) as per the published opinion-based recommendations from EUSOMA 
and NICE in elderly women with BC in a rural state such as WV and a nationally representative 
population from the SEER-Medicare data, and to determine the factors associated with timely 
BC care in these study cohorts.  The study findings indicate that the two study cohorts were 
statistically different in terms of most of their characteristics.  The median number of days for 
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BC diagnosis was higher in WV-Medicare cohort as compared to that from the SEER-Medicare 
cohort.  In addition, WV-Medicare cohort was significantly less likely to receive timely 
diagnosis of BC as compared to the SEER-Medicare cohort after controlling for all the factors.  
This difference of timely BC diagnosis between the WV-Medicare and SEER-Medicare cohorts 
may be a reflection of WV women’s social and cultural barriers in form of psychosocial factors 
such as fear, sense of fatalism, knowledge and beliefs, perceived risk, social norms, physicians’ 
characteristics, and health system factors such as cultural variations in BC detection and follow-
up, or preferences in cancer detection 
19,50-56
 which are not measured in this study.   Future 
studies may assess the effects of these factors that may contribute to diagnosis delays in this rural 
state.  Efforts to expedite diagnostic evaluations after any breast abnormality and abnormality in 
screenings may help reduce untimely BC diagnosis in elderly WV women.   
Among the predictors of timely BC diagnosis, higher annual household income was 
significantly associated with timely diagnosis of BC in the WV-Medicare cohort.  This finding 
was consistent with the previous studies which identified association between lower income and 
delayed BC diagnosis 
57-59
.  Again consistent with previous studies, WV women with tumor size 
less than 1 cm was associated with delayed BC diagnosis as compared to women with tumor size 




The median days for initiation of BC treatment after diagnosis was lower in WV women 
as compared to those from the SEER-Medicare data.  This finding is consistent with previous 
studies 
16,63
 in which the authors argued that rural women who may have to travel longer 
distances for evaluations and treatments might well be referred for treatment on that same day to 
minimize travel 
63
.  Also, the median days from initiation of surgery, chemotherapy or radiation 
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therapy did not vary much by stage at BC diagnosis for both the study cohorts.  Within women 
who have had surgery as their first BC treatment, those with regional and local stage cancers had 
higher median days of treatment for the WV-Medicare cohort.  Within those who had 
chemotherapy as their first BC treatment, women with distant cancer had lowest median days for 
the WV-Medicare cohort.  Furthermore, there were no significant differences in timely treatment 
of BC between WV-Medicare and SEER-Medicare cohorts after controlling for all the factors.  
This indicates that rural and low income population in a state such as WV is equally likely to 
receive timely BC treatment as the SEER-Medicare population.  This finding is remarkable since 
rural settings are less likely to have specialized equipment or trained healthcare professionals 
64
.  
An interesting finding of this study is that there were no significant predictors of timely BC 
treatment in the WV-Medicare cohort thereby indicating that several unmeasured factors such as 
health status, body mass index (BMI), psychosocial factors such as fear, fatalism, knowledge and 
beliefs, and health system factors may be affecting timely BC treatment in these rural WV 
women.   
Finally, it was found that WV-Medicare cohort had surprisingly higher probability of 
being alive at the end of the follow-up period of three years after controlling for timeliness of BC 
care.  Given the prognosis of the disease and higher five-years survival in women with BC 
3
, the 
follow-up period of three years to model probability of being alive in elderly women who receive 
timely BC care may not generate robust statistical estimates for this association to make any 
conclusions in this regards.  Future studies to assess the effect of timely BC care in elderly 
women with BC on survival and how it varies between the rural setting and the national 




 This study’s interpretation is limited by the nature of the cancer registry-Medicare linked 
dataset.  Since administrative claims were utilized for the analyses of timeliness of BC care, any 
healthcare services received outside of the Medicare settings may not be captured which may 
affect the precision of the estimates.  Also, these data could only identify procedures and 
diagnoses that healthcare providers include on billings on the dates of services and hence could 
not determine types of BC symptoms or the sequence of procedures occurred on the same date.  
For instance, if the diagnostic mammography and MRI had the same claim date for a particular 
woman then it was not possible to identify which procedure occurred first.  In addition, the 
typical sequence of events which leads to BC diagnosis depends on whether the abnormality in 
the breast was first detected by the patient, or the clinician, or through the screening 
mammogram 
19
.  Since this study utilized administrative claims data, whether diagnosis of BC 
was affected by patient-related factors (patient delay) or system-related factors (structural delay) 
was not identified and hence was not controlled in the analyses.  Adjuvant therapy with 
prescription drugs was not captured in the analyses as these were not covered by Medicare prior 
to 2007.  Several important variables such as annual household income, education level, access 
to BC screening centers and hospitals offering oncology services are not available in the cancer 
registries-Medicare linked databases and hence census tract information for these variables were 
utilized 
65
.  Data on some important variables which may affect timeliness of BC care such as 
health status, severity of comorbidities, and patient preferences were not available.  This study 
included individuals who received BC treatment in the form of surgery, radiation, and 
chemotherapy within one year after diagnosis and hence the findings cannot be generalized to 
individuals who do not receive any treatment.  As this study is based on observational data, the 
study findings cannot establish causality.  In addition, the findings of this study are only 
73 
 
generalizable to elderly BC patients covered only by Medicare.  Also, the findings are not 
generalizable to other rural populations.  Despite these limitations, this study provides important 
inputs on the timeliness of BC care and associated health outcomes in a BC population that is 
aged, belongs to a lower socio-economic status, and from a rural state such as WV. 
CONCLUSION 
 Timely BC diagnosis is a critical concern in a rural state such as WV as women in this 
state are less likely to get timely BC diagnosis when compared to their national counterparts, 
however the chances of their survival are higher.  Interventions that address patient, provider and 
health system factors which contribute to delay in BC diagnosis in WV are needed to be 
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Figure 3.1:  The Andersen Behavioral Model for Health Care Utilization (For Aim 2) 
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Figure 3.2:  Proportion of Study Cohorts Receiving Timely Breast Cancer Diagnosis as Per 






Figure 3.3:  Proportion of Study Cohorts Receiving Timely Breast Cancer Treatment as 
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Description of the Study Cohorts 
2003-2006 




(N=36,276)   
    N % N % Sig 
Age at Diagnosis 
    
*** 
 
66-69 275 19.8 7,975 22.0 
 
 
70-74 385 27.7 9,079 25.0 
 
 
75-79 379 27.3 8,624 23.8 
 
 
80,+ 349 25.1 10,598 29.2 
 Race 
     
*** 
 
White 1,355 97.6 32,124 88.6 
 
 
Other 33 2.4 4,152 11.4 
 Location of Residence 
    
*** 
 
Metro 762 54.9 30,349 83.7 
 
 
Non-metro 626 45.1 5,927 16.3 
 Census Tract Household Income 
   
*** 
 
LE $35,000 1,268 91.4 8,949 24.7 
 
 
GT $35,000 120 8.6 27,327 75.3 
 Census Tract Education 
    
*** 
 
LT 15% pop. with CE 704 50.7 11,005 30.3 
 
 
GE 15% pop. with CE 684 49.3 25,271 69.7 
 Stage at Diagnosis 
    
* 
 
Insitu 209 15.1 5,982 16.5 
 
 
Local 866 62.4 20,982 57.8 
 
 
Regional 274 19.8 8,166 22.5 
 
 
Distant 38 2.7 1,146 3.2 
 Grade of Tumor 
    
*** 
 
Well Differentiated 325 23.4 7,762 21.4 
 
 
Moderately Differentiated 473 34.1 14,258 39.3 
 
 
Poorly Differentiated 306 22.0 9,252 25.5 
 
 
Undifferentiated/Unknown 284 20.5 5,004 13.8 
 ER Status 
     
*** 
 
Positive 628 45.2 25,018 69.0 
 
 
Negative 126 9.1 5,114 14.1 
 
 
Borderline/Unknown 634 45.7 6,144 16.9 
 Tumor Size 
     
*** 
 
<1 cm 290 29.5 7,992 22.6 
 
 
1-2 cm 409 41.6 13,809 39.1 
 
 
2-3 cm 158 16.1 5,485 15.5 
 
 
>3 cm 126 12.8 7,999 22.7 
 Comorbidity 
    
*** 
 
0 716 51.6 20,890 57.6 
 
 
1 416 30.0 9,796 27.0 
 
 
2,+ 256 18.4 5,590 15.4 
 Mental Condition 
    
*** 
 
Yes 134 9.7 2,256 6.2 
 
 
No  1,254 90.3 34,020 93.8 
 PCP visits 
      
 
High 689 49.6 17,851 49.2 
 
 
Low 699 50.4 18,425 50.8 




Description of the Study Cohorts 
2003-2006 




(N=36,276)   
    N % N % Sig 
Total BC Screening Centers 





High 587 42.3 17,714 48.8 
 
 
Low 801 57.7 18,562 51.2 




High 551 39.7 16,157 44.5 
 
 
Low 837 60.3 20,119 55.5 
               
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  FFS, Fee-for-service; WV, West Virginia; SEER, Surveillance, 
Epidemiology, and End Results; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC, Breast Cancer; CE, College 
Education; pop., population; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig, 
Significance. Asterisks represent statistically significant group differences based on χ2 tests: ***P<0.001; **001<=P<.01 ; 





Median Days in Diagnosis and Treatment for the Study Cohorts 
2003-2006 
    WV-Medicare (N=1,388) SEER-Medicare (N=36,276) 
Type of Delay 









        Initial Consultation to Diagnosis 892 26 12 to 50 35,717 20 8 to 41 
        
Diagnosis to Treatment 851 8 0 to 28 34,695 15 0 to 29 
 
Diagnosis to Surgery 738 0 0 to 25 31,779 14 0 to 28 
 
Diagnosis to Chemotherapy 39 20 15 to 29 1,329 25 14 to 45 
 
Diagnosis to Radiation 74 27 16 to 48 1,587 28 15 to 49 
                
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 







Median Days (IQR) for Type of Initial Treatment by Stage at Diagnosis 
For the Study Cohorts 
2003-2006 
 
    WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 
Stage at 













        Insitu 
 
0 (0 to 20) 11 (0 to 28) 178 (178 to 178) 21 (8 to 34) 31 (24 to 64) 28 (19 to 46) 
Local 
 
0 (0 to 26) 14 (0 to 28) 20 (15 to 51) 29 (15 to 50) 27 (16 to 48) 30 (17 to 49) 
Regional 
 
9 (0 to 25) 15 (0 to 29) 21 (11 to 27) 25 (14 to 42) 17 (14 to 55) 29 (15 to 54) 
Distant 
 
10 (0 to 24) 14 (0 to 29) 17 (15 to 31) 24 (14 to 49) 25 (4 to 44) 13 (4 to 42) 
                
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 





Median Days in Diagnosis and Treatment within Independent Variables for the Study Cohorts 
2003-2006 
    Initial Consultation to Diagnosis Diagnosis to Treatment 
Variables  WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 









    892   35,717   851   34,695   









66-69 167 27 (13 to 50) 7,827 21 (9 to 43) 170 8 (0 to 28) 7,825 14 (0 to 28) 
 
70-74 245 27 (12 to 55) 8,961 21 (9 to 42) 239 0 (0 to 23) 8,863 15 (0 to 29) 
 
75-79 238 26 (13 to 49) 8,496 21 (9 to 41) 226 10 (0 to 31) 8,337 15 (0 to 30) 
 








White 876 26 (12 to 49) 31,639 20 (8 to 41) 835 8 (0 to 28) 30,796 15 (0 to 29) 
 
Other 16 20 (8 to 53) 4,078 22 (9 to 47) 16 16 (0 to 34) 3,899 19 (0 to 36) 
Location of Residence 
  
*** 




Metro 469 27 (13 to 51) 29,901 21 (8 to 42) 444 9 (0 to 28) 29,045 16 (0 to 31) 
 
Non-metro 423 24 (11 to 48) 5,816 18 (8 to 36) 407 7 (0 to 28) 5,650 12 (0 to 25) 







LE $35,000 817 26 (12 to 51) 8,775 20 (8 to 41) 779 6 (0 to 27) 8,447 14 (0 to 29) 
 
GT $35,000 75 24 (10 to 38) 26,942 20 (8 to 41) 72 17 (0 to 36) 26,248 15 (0 to 30) 
Census Tract Education 




LT 15% pop. 
with CE 456 26 (12 to 52) 10,822 20 (9 to 42) 441 10 (0 to 30) 10,463 14 (0 to 29) 
 
GE 15% pop. 
with CE 436 27 (11 to 48) 24,895 20 (8 to 41) 410 6 (0 to 25) 24,232 16 (0 to 30) 









Insitu 151 35 (20 to 64) 5,904 28 (14 to 58) 144 0 (0 to 27) 5,705 12 (0 to 28) 
 
Local 553 27 (13 to 51) 20,797 21 (9 to 41) 525 9 (0 to 29) 20,209 15 (0 to 29) 
 
Regional 164 17 (8 to 37) 8,029 16 (6 to 34) 162 11 (0 to 26) 7,883 17 (0 to 31) 
 
Distant 23 7 (4 to 17) 987 7 (1 to 21) 19 17 (4 to 41) 898 18 (6 to 37) 
Grade of Tumor ** 
 
*** 




Well D 204 29 (15 to 54) 7,695 22 (10 to 44) 194 0 (0 to 29) 7,505 15 (0 to 29) 
 
Moderately D 302 24 (11 to 50) 14,074 20 (8 to 40) 295 9 (0 to 29) 13,735 15 (0 to 30) 
 
Poorly D 191 20 (8 to 43) 9,098 17 (7 to 35) 189 10 (0 to 26) 8,993 16 (0 to 29) 
 
Undifferentiated










Positive 389 24 (10 to 48) 24,664 20 (8 to 40) 365 13 (0 to 30) 24,080 15 (0 to 30) 
 
Negative 78 23 (10 to 41) 5,022 17 (7 to 36) 77 9 (0 to 22) 4,996 16 (0 to 30) 
 
Borderline/Unkn
own 425 27 (13 to 52) 6,031 25 (11 to 50) 409 0 (0 to 28) 5,619 13 (0 to 29) 




Median Days in Diagnosis and Treatment within Independent Variables for the Study Cohorts 
2003-2006 
    Initial Consultation to Diagnosis Diagnosis to Treatment 
Variables  WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 









    892   35,717   851   34,695   
Tumor Size *** 
 
*** 




<1 cm 191 29 (17 to 49) 7,921 26 (12 to 52) 185 0 (0 to 31) 7,824 13 (0 to 28) 
 
1-2 cm 255 26 (10 to 48) 13,675 20 (8 to 39) 240 14 (0 to 29) 13,379 14 (0 to 29) 
 
2-3 cm 99 19 (8 to 44) 5,430 16 (7 to 34) 90 12 (0 to 28) 5,279 16 (0 to 30) 
 








0 458 24 (12 to 47) 20,550 20 (8 to 40) 438 5 (0 to 28) 20,111 15 (0 to 29) 
 
1 268 27 (10 to 49) 9,650 21 (9 to 42) 265 10 (0 to 29) 9,361 15 (0 to 29) 
 




     
 
Yes 87 23 (11 to 49) 2,227 21 (9 to 42) 83 9 (0 to 28) 2,104 14 (0 to 29) 
 








High 455 27 (12 to 53) 17,635 22 (10 to 45) 430 7 (0 to 28) 17,004 15 (0 to 29) 
 
Low 437 25 (11 to 48) 18,082 19 (7 to 37) 421 9 (0 to 28) 17,691 15 (0 to 30) 
Total BC Screening Centers 






High 374 27 (13 to 52) 17,449 21 (8 to 42) 353 2 (0 to 22) 16,929 18 (0 to 33) 
 
Low 518 26 (11 to 48) 18,268 20 (8 to 40) 498 13 (0 to 32) 17,766 13 (0 to 27) 
Total Hospitals with Oncology Services *** 
 
** 
   
 
High 351 27 (12 to 51) 15,924 21 (8 to 43) 330 1 (0 to 23) 15,427 19 (0 to 33) 
 
Low 541 26 (12 to 48) 19,793 20 (8 to 40) 521 13 (0 to 31) 19,268 13 (0 to 27) 
                    
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 
Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC, 
Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; IQR, Inter Quartile 
Range; Sig, Significance. Asterisks represent statistically significant group differences based on Kruskal-Wallis tests: 








Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions 
2003-2006 
    WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 
    Timely Diagnosis Timely Diagnosis Timely Treatment Timely Treatment 
Variables Model 1 Model 2 Model 3 Model 4 
    AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Age at Diagnosis 
           
 
66-69 0.98 [0.59,1.64] 
 
0.81 [0.76,0.87] *** 1.55 [0.87,2.77] 
 
1.23 [1.14,1.32] *** 
 
70-74 0.79 [0.49,1.28] 
 
0.83 [0.78,0.89] *** 1.72 [0.99,3.01] 
 
1.17 [1.09,1.25] *** 
 
75-79 0.88 [0.54,1.42] 
 
0.87 [0.81,0.93] *** 1.07 [0.63,1.80] 
 











            
 
White 1.31 [0.25,6.75] 
 
1.21 [1.12,1.30] *** 0.91 [0.09,8.84] 
 










Location of Residence 











Non-metro 1.40 [0.91,2.17] 
 
1.30 [1.20,1.40] *** 1.47 [0.90,2.40] 
 
1.28 [1.18,1.39] *** 
Census Tract Household Income 
          
 















Census Tract Education 
          
 









GE 15% pop. with CE 0.77 [0.48,1.22] 
 
1.07 [1.01,1.14] * 1.45 [0.84,2.52] 
 
0.94 [0.88,1.00] * 
Stage at Diagnosis 
           
 
Insitu 0.19 [0.02,1.57] 
 
0.33 [0.27,0.39] *** 0.74 [0.14,4.02] 
 
1.37 [1.17,1.61] *** 
 
Local 0.23 [0.03,1.86] 
 
0.51 [0.42,0.61] *** 0.76 [0.15,3.77] 
 
1.23 [1.05,1.43] ** 
 
Regional 0.28 [0.03,2.28] 
 
0.60 [0.50,0.73] *** 0.91 [0.18,4.71] 
 














Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions 
2003-2006 
    WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 
    Timely Diagnosis Timely Diagnosis Timely Treatment Timely Treatment 
Variables Model 1 Model 2 Model 3 Model 4 
    AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
Grade of Tumor 
           
 









Moderately D 1.34 [0.85,2.11 
 





Poorly D 1.32 [0.77,2.26] 
 


































Borderline/Unknown 1.22 [0.80,1.87] 
 





            
 
<1 cm 0.48 [0.23,0.97] * 0.66 [0.61,0.71] *** 0.59 [0.27,1.31] 
 
1.22 [1.13,1.32] *** 
 
1-2 cm 0.58 [0.30,1.12] 
 
0.90 [0.84,0.96] ** 0.63 [0.30,1.34] 
 
1.20 [1.12,1.29] *** 
 






1.12 [1.03,1.21] ** 
 




















1 0.72 [0.48,1.08] 
 





2,+ 0.65 [0.41,1.04] 
 
0.84 [0.78,0.90] *** 0.92 [0.53,1.60] 
 
0.81 [0.76,0.88] *** 
Mental Condition 
           
 





















Factors Associated with Timely Diagnosis and Timely Treatment Separately for the Study Cohorts 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions 
2003-2006 
    WV-Medicare SEER-Medicare WV-Medicare SEER-Medicare 
    Timely Diagnosis Timely Diagnosis Timely Treatment Timely Treatment 
Variables Model 1 Model 2 Model 3 Model 4 
    AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig AOR 95% CI Sig 
PCP visits 
            
 
High 0.84 [0.59,1.21] 
 
0.77 [0.73,0.81] *** 1.05 [0.70,1.57] 
 










Total BC Screening Centers 
          
 

















Total Hospitals with Oncology Services 
         
 






0.71 [0.67,0.75] *** 
 







                              
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed with primary incident breast cancer from 2003 to 
2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary 
Care Physicians, BC, Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; AOR, Adjusted Odds Ratio; CI, Confidence 
Interval; Sig, Significance; NA, Not Applicable. The regressions also include intercept terms and parameter estimates for other variable controlled are not presented.  Model 1 
represents Timely Care from Initial Consultation to Diagnosis for WV-Medicare cohort; Model 2 represents Timely Care from Initial Consultation to Diagnosis for SEER-
Medicare cohort; Model 3 represents Timely Care from Diagnosis to Treatment for WV-Medicare cohort; Model 4 represents Timely Care from Diagnosis to Treatment for SEER-
Medicare cohort. "Non-timely care for Diagnosis", was the reference group for Models 1 and 2 for respective cohorts for the dependent variable, and "Non-timely care for 
Treatment" was the reference group for Models 3 and 4 for respective cohorts for the dependent variable.  Asterisks represent statistically significant group differences compared 





Differences in Timely Diagnosis and Treatment between Study Cohorts 
In a Multivariate Framework 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions  
2003-2006 
 
  WV-Medicare 
    Timely Diagnosis Timely Treatment 
Variables Model 1 Model 2 
    AOR 95% CI Sig AOR 95% CI Sig 
        Type of Setting 
      
 







Age at Diagnosis 
      
 
66-69 0.82 [0.76,0.87] *** 1.23 [1.15,1.32] *** 
 
70-74 0.83 [0.78,0.89] *** 1.18 [1.10,1.26] *** 
 








      
 






Location of Residence 







Non-metro 1.31 [1.21,1.41] *** 1.27 [1.18,1.38] *** 
Census Tract Household Income 
     
 









Census Tract Education 
      
 









Stage at Diagnosis 
      
 
Insitu 0.32 [0.27,0.39] *** 1.36 [1.16,1.60] *** 
 
Local 0.50 [0.42,0.60] *** 1.22 [1.05,1.42] * 
 






Grade of Tumor 
      
 





Moderately Differentiated 1.09 [1.03,1.16] ** 0.99 [0.92,1.05] 
 
 
Poorly Differentiated 1.26 [1.17,1.36] *** 1.04 [0.96,1.12] 
 
 




        




Differences in Timely Diagnosis and Treatment between Study Cohorts 
In a Multivariate Framework 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions  
2003-2006 
 
  WV-Medicare 
    Timely Diagnosis Timely Treatment 
Variables Model 1 Model 2 
    AOR 95% CI Sig AOR 95% CI Sig 
ER Status 












Borderline/Unknown 0.86 [0.81,0.92] *** 1.07 [0.99,1.15] 
 
Tumor Size 
      
 
<1 cm 0.66 [0.62,0.71] *** 1.21 [1.12,1.31] *** 
 
1-2 cm 0.90 [0.84,0.96] ** 1.19 [1.11,1.28] *** 
 
2-3 cm 1.06 [0.97,1.15] 
 
1.11 [1.02,1.20] * 
 












1 0.92 [0.88,0.98] ** 0.96 [0.90,1.01] 
 
 
2,+ 0.83 [0.78,0.89] *** 0.82 [0.76,0.88] *** 
Mental Condition 
      
 










      
 






Total BC Screening Centers 
      
 







Total Hospitals with Oncology Services 
     
 
High NA NA 
 
0.72 [0.68,0.76] *** 
 
Low NA NA 
 
1 
                  
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 
Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary Care Physicians, BC, 
Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; AOR, Adjusted Odds 
Ratio; CI, Confidence Interval; Sig, Significance; NA, Not Applicable. The regressions also include intercept terms and 
parameter estimates for other variable controlled are not presented.  Model 1 represents Timely Care from Initial Consultation to 
Diagnosis; Model 2 represents Timely Care from Diagnosis to Treatment. "Non-timely care for Diagnosis" and "Non-timely care 
for Treatment" are the reference groups for Model 1 and Model 2, respectively for the dependent variables.  Asterisks represent 




Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions  
2003-2006 
 
  WV-Medicare 
Variables   Model 1 Model 2 
    AOR 95% CI Sig AOR 95% CI Sig 
Type of Setting 
 
   
  
 
WV-Medicare 7.79 [3.33,18.20] *** 6.82 [2.89,16.1] *** 
 




















Timely Treatment   
 
   
 Yes NA NA  1.17 [1.04,1.31] * 
 No  NA NA  1   







66-69 5.06 [4.27,6.00] *** 4.55 [3.83,5.40] *** 
 
70-74 3.10 [2.70,3.56] *** 2.87 [2.49,3.31] *** 
 
75-79 2.45 [2.15,2.80] *** 2.29 [2.00,2.62] *** 
 
























































Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions  
2003-2006 
 
  WV-Medicare 
Variables   Model 1 Model 2 
    AOR 95% CI Sig AOR 95% CI Sig 




LT 15% pop. with CE 1   1 
  
 
GE 15% pop. with CE 1.20 [1.06,1.35] ** 1.19 [1.05,1.36] * 
Stage at Diagnosis 
 
   
  
 
Insitu 34.91 [25.5,47.6] *** 34.75 [25.0,48.1] *** 
 
Local 11.07 [8.72,14.0] *** 11.13 [8.72,14.2] *** 
 
Regional 6.56 [5.18,8.31] *** 6.20 [4.87,7.89] *** 
 
















Moderately D 0.87 [0.74,1.02] 
 
0.84 [0.71,0.99] * 
 
Poorly D 0.61 [0.51,0.72] *** 0.58 [0.48,0.69] *** 
 
Undifferentiated/Unknown 0.73 [0.60,0.89] ** 0.80 [0.65,1.00] * 
ER Status    
 
   
 Positive 1  
 
1   
 Negative 0.49 [0.43,0.57] *** 0.49 [0.43,0.57] *** 








<1 cm 2.85 [2.38,3.42] *** 2.67 [2.22,3.22] *** 
 
1-2 cm 2.30 [2.01,2.63] *** 2.35 [2.04,2.70] *** 
 
2-3 cm 1.50 [1.30,1.74] *** 1.49 [1.29,1.73] *** 
 
>3 cm 1   1 
  
      (Continued)… 




Differences in Survival between Study Cohorts with Receipt of Timely Diagnosis and Timely Treatment in a Multivariate Framework 
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions  
2003-2006 
 
  WV-Medicare 
Variables   Model 1 Model 2 













1 0.64 [0.57,0.72] *** 0.64 [0.56,0.73] *** 
 








Yes 0.64 [0.53,0.77] *** 0.70 [0.58,0.85] *** 
 









High 0.84 [0.75,0.93] ** 0.87 [0.78,0.97] ** 
 
Low 1   1 
  
Total Hospitals with BC Screening Services  
  
 









Total Hospitals with Oncology Services 
 
       
 High NA NA 
 
1.12 [1.00,1.26]  
 Low NA NA 
 
1   
        
Note: Based on 1,388 elderly WV-Medicare women and 36,276 elderly SEER-Medicare women, age 66 and above diagnosed with primary incident breast cancer from 2003 to 
2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CE, College Education; pop., population; D, Differentiated; ER, Estrogen-receptor; PCP, Primary 
Care Physicians, BC, Breast Cancer; LE, Less than or equal to; GT, Greater than; LT, Less than; GE, Greater than or equal to; NA, Not Applicable; AOR, Adjusted Odds Ratio; 
CI, Confidence Interval; Sig, Significance. The regressions also include intercept terms and parameter estimates for other variable controlled are not presented.  Model 1 represents 
Survival After Controlling for Timely Diagnosis; Model 2 represents Survival after Controlling for Timely Treatment. "Death" is the reference group for the dependent variables 





















































TOTAL HEALTHCARE COSTS AMONG ELDERLY WOMEN WITH BREAST 
CANCER IN THE INITIAL PERIOD OF ONE YEAR AFTER DIAGNOSIS: AN 




Breast cancer (BC), the most common type of cancer, is the second leading cause of 
cancer death in women in the United States (US).  It is estimated that approximately 232,670 
new cases of invasive BC, and about 62,570 new cases of carcinoma in situ (CIS) will be 
diagnosed, and 40,000 women will die from BC in the US in 2014 
1
.  Based on Surveillance, 
Epidemiology and End Results (SEER) statistics for 2005-2009, the overall incidence of BC 
from 2005-2009 was 82.97 per 100,000 in women age below 65 years and was 421.30 per 
100,000 in women age 65 and above 
2
.  The overall mortality from BC from 2005-2009 was 
11.15 per 100,000 in women below 65 years of age and was 98.64 per 100,000 in women age 65 
and above 
2
.   
Total Healthcare Costs in the Initial Phase of One Year after Breast Cancer Diagnosis 
 Due to rapid scientific and technological advances in the field of oncology and with 
increased adoption and utilization of more expensive cancer treatments as the standards of care, 
and due to an increasing aging population, the costs of cancer care is expected to increase 
enormously in the future.  Based on a recent study, the national costs of cancer care in 2010 was 
estimated to be $124.6 billion, out of which female BC comprised the highest proportion of 13% 
($16.5 billion), which may increase by 32% in 2020 
3
.  In addition, BC had the highest 





From $16.5 billion, 37% of the BC costs were for the initial phase of care, 41% were for the 
continuing phase of care and 22% were for the last year of life.   
A descriptive review on the costs of cancer care in the US reported that studies vary 
widely with regards to study settings, methodology, cost perspective, stage at diagnosis, 
populations, measurements of costs, types of services included, time horizons, and databases 
4
.  
Moreover, none of the studies included in the review followed any published standards of 
reporting costs analyses and hence called for future studies to follow these standards 
4
.  A 
systematic review of costs associated with BC in the US reported that the lifetime per-patient 
direct medical care cost estimates of BC ranged from $20,000 to $100,000 for a base cost year 
from 1984 to 2003 
5
.  Yet the authors of this review suggested that the majority of the studies 
included in the review were outdated, and hence the findings of the study did not reflect the 
changes in patterns of care due to technological advances and innovations in BC treatment 
5
.  
Also, most of the studies included in the review focused on women with BC stages disease I or II 
5
. 
 The costs to Medicare of BC care are substantially higher during the initial phase of care 
due to surgery, radiation and adjuvant therapy 
5-9
.  Despite the extensive cost to Medicare during 
the initial phase of care, there is inadequate information on costs incurred by types of specific 
services, and average costs by stage at diagnosis, type of treatment, and number of comorbidities, 
and the factors associated with higher costs of BC care.  Recent studies on costs of cancer care in 
the initial phase of care for elderly BC patients in the US have been based on old data (2003), 
from fewer cancer registries, or for fewer disease stages 
3,6,7,10
.  In addition, the average costs by 
type of specific services, stage at diagnosis, type of initial treatment, and comorbidities have not 
been reported 
7,10
.  One study which determined the initial phase of care costs for Medicare 
98 
 
beneficiaries in Virginia reported lower costs associated with BC care as compared to that from 
the SEER-Medicare data, and that comorbidity, hospital stay, and type of treatment were 
significant contributors of costs due to BC 
11
.  However, there is limited information available 
about the costs associated with BC care from rural settings and from non-SEER states.  The costs 
estimates from the previous studies may not be representative of Medicare reimbursements for 
other geographic areas and across other populations in the US.   
The population in WV is predominantly white and a considerable proportion reside in 
rural areas.  WV also has high poverty rates, low levels of education, aging population, high rates 
of chronic diseases, and poor health behaviors 
12-15
.   With lower incidence of BC among WV 
women age 65 and older (372.8 per 100,000 vs. 410.6 per 100,000) but higher mortality (110.4 
per 100,000 vs. 98.6 per 100,000) 
16,17
 than national estimates, and with higher rates of advanced 
and unstaged BC in these women 
18-22
, it is likely that costs of BC care during the initial phase of 
care may be higher.  These findings will help to determine the extent to which costs are higher in 
rural, underserved states such as WV with increasing median age.   
 Thus, the purpose of the study is to determine the average costs in the initial phase of care 
among WV-Medicare fee-for-service (FFS) women beneficiaries and compare it with national 
estimates derived from SEER-Medicare data, and to determine the factors associated with higher 
costs in WV-Medicare women and compare it with the national estimates, after controlling for 
predisposing factors (age, race), enabling factors (median household income, education level), 
need-related factors (stage at diagnosis, grade of tumor, estrogen-receptor (ER) status, co-
occurring physical and mental chronic conditions), healthcare use factors (number of primary 
care physicians (PCP) visits in the year prior to BC diagnosis, type of initial cancer-related 
treatment, inpatient stay) and external healthcare environmental factors (location of residence 
99 
 
and number of hospitals offering oncology services in the area of residence).  The post hoc 
objective of the study is to utilize linear decomposition technique 
23,24
 to determine the 
magnitude of differences in the average costs in the initial phase of care between WV-Medicare  
and the SEER-Medicare, and to understand extent to which the predisposing, enabling, need, 
healthcare use, and external healthcare environmental factors explain the differences in the 





West Virginia Cancer Registry-Medicare-Area Resource File linked dataset 
The West Virginia Cancer Registry (WVCR) was established by the West Virginia 
Department of Health and Human Resources in 1993 and it is a state-level cancer registry which 
provides information on cancer incidence and mortality in West Virginia (WV) 
25
.  The WVCR 
collects and provides data on primary site of cancer, tumor grade, date and stage of diagnosis, 
date and cause of mortality, and demographics such as age, gender, race, and also zip code (for 
location of residence).  The de-identified linked WVCR-Medicare dataset was developed at West 
Virginia University (WVU) in full compliance with the WVU Institutional Review Board and 
HIPPA requirements 
26
.  The WVCR file served as the case source file from which the 
information about individuals aged ≥ 65 years and diagnosed with cancer between the January 1, 
2002 and December 31, 2007 was obtained.  The Social security numbers (SSN) for these 
individuals were provided to the CMS by the WVCR, using which the CMS identified the 
corresponding Health Insurance Claim (HIC) number.   A “crosswalk” file created using the HIC 
allowed for linkage across the WVCR and the Medicare for extracting information on these 
individuals as Medicare beneficiaries.  Individuals with a missing SSN were excluded from the 
100 
 
linkage.  The Area Resource File (ARF) was linked to the WVCR-Medicare dataset using the 
state and county FIPS codes for each beneficiary to extract the county level information on the 
availability of healthcare facilities, healthcare providers, and socioeconomic characteristics of the 
region’s population. 
SEER-Medicare-Area Resource File linked dataset 
The SEER-Medicare linked dataset provides population-based information on cancer-
related epidemiologic and health services research.  The SEER-Medicare program collects 
information on newly diagnosed cases of cancer from 17 population-based tumor registries 
which collect information from several sources including hospitals, outpatient clinics, 
laboratories, private practitioners, hospices, autopsy reports and death certificates.  The SEER-
Medicare data represents approximately 26% of the US population.  It is in the form of a 
customized file known as the Patient Entitlement and Diagnosis Summary File (PEDSF) which 
contains one record per person for individuals in the SEER database who have been matched 
with Medicare enrollment records.  It provides diagnostic information for up to 10 diagnosed 
cancer cases (including date of cancer diagnosis, cancer sub-site, cancer stage at diagnosis, tumor 
size, histology, grade), and information on the first course of cancer related treatment (surgery 
and radiation provided in the first 4 months after diagnosis) for each individual.  The PEDSF 
additionally includes information on the median household income and education level for each 
individual based on their census tract and zip code data.  
The Medicare files that are a part of the SEER-Medicare linked dataset provide 
information about any health care utilized in the inpatient, outpatient, physician, home health, 
and hospice care by individuals age 65 and above who are enrolled in and are covered under the 
Medicare program.  All Medicare files include specific dates of service and codes for specific 
101 
 
diagnosis and procedures using the International Classification of Disease, Ninth Edition (ICD-9) 
codes or Common Procedure Terminology codes.  The linkage of the SEER data with the 
Medicare data, and formation of the SEER case number involves matching individuals across the 
two files using an algorithm based on a match of SSN, name, sex, and date of birth.  The linkage 
process is described elsewhere 
27
.  The Area Resource File (ARF) was linked to the SEER-
Medicare dataset using the state and county Federal Information Processing Standards (FIPS) 
code for each beneficiary to get the county level information on the availability of healthcare 
facilities and healthcare providers. 
Study Design 
 This study utilized a retrospective observational cohort design to assess healthcare costs 
during initial phase of care in Medicare FFS beneficiaries diagnosed with BC. 
Study Cohorts 
The two study cohorts comprised of women from WVCR-Medicare-ARF linked dataset 
and SEER-Medicare-ARF linked dataset, age 66 and above at the first primary diagnosis of 
incident BC between January 1, 2003 to December 31, 2006.  These women were required to be 
continuously enrolled in Medicare parts A and B at least 12 months prior to the BC diagnosis to 
identify chronic conditions to measure comorbidity and till the follow up period of 12 months 
after BC diagnosis to determine average total costs, and not enrolled in health maintenance 
organizations (HMOs) at any time during this period.  Women with a previous cancer diagnosis, 
having an unknown or missing BC stage information, and who were diagnosed via death 
certificate or autopsy were excluded from the study.  Also women who died during the first 12 
months after BC diagnosis were excluded from the study as these women may have dramatically 
higher total average costs which may affect the estimates 
9,11
.  Each beneficiary was followed for 
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up to 12 months after BC diagnosis, to determine healthcare costs during the initial phase of care.  
BC diagnosis codes were based on the primary site and International Classification of Diseases, 
9th edition Clinical Modification (ICD-9-CM) codes 174.xx, 233.0x, 238.3x, and 239.3x. 
The WVCR-Medicare-ARF linked dataset identified 2,814 women diagnosed with BC 
from January 1, 2003 to December 31, 2006.  The following women were excluded from the 
final study cohort: 152 women who were below 66 years at diagnosis, 13 women who died 
during the first 12 months after BC diagnosis, 526 women with any previous cancer diagnosis, 
24 women who were diagnosed with BC during death or autopsy, 245 women with unknown or 
missing BC stage, 234 women who were not continuously enrolled in Medicare parts A and B in 
the 12 months before and 12 months after diagnosis, and 232 women who were members of a 
HMO at any time during the study period.  From the remaining 1,388 women, only 1 woman 
(0.07%) had zero total expenditure in the initial period after BC diagnosis and hence was 
removed from the analyses.  Thus, a sample of 1,387 women was included in the final analyses. 
The SEER-Medicare-ARF linked dataset had 112,719 women diagnosed with BC from 
January 1, 2003 to December 31, 2006.  The following women were excluded from the final 
study cohort: 44,869 women who were below 66 years at diagnosis, 6,137 women who died 
during the first 12 months after BC diagnosis, 3,123 women with any previous cancer diagnosis, 
2 women who were diagnosed with BC during death or autopsy, 1,299 women with unknown or 
missing BC stage, 3,292 women who were not continuously enrolled in Medicare parts A and B 
in the 12 months before and 12 months after diagnosis, and 14,296 women who were members 
of a HMO at any time during the study period.  From the remaining 39,701 women, 176 women 
(0.44%) had zero total costs in the initial phase of care and hence were removed from the 




Cost Estimates:  Costs of care in the initial phase of care were separately calculated for both the 
study cohorts.  All Medicare files including Inpatient (Medicare Analysis and Procedure), 
Hospital Outpatient, Carrier/NCH, Hospice, Skilled Nursing Facility, Home Health Agency, and 
Durable Medical Equipment, were used to estimate average direct medical costs in the initial 
phase of care.  In addition to total direct medical costs of care, average direct medical costs 
within the categories of care such as inpatient services, outpatient services, physician services, 
and other services (costs related to durable medical equipment, hospice care and home health 
agency) were determined for both the study cohorts.  The prescription drug costs were not 
included in the analysis as data pertaining to prescription drugs was not available for the years of 
the study. 
The initial phase of care was defined as the year following BC diagnosis, based on the 
following reasons cited by previous studies: initial course of treatment including adjuvant 
therapy to be completed within one year of diagnosis, initial phase of care is also based on the 
consensus from a group of clinical oncologists, and it could be used for comparison purposes 
with previous literature 
6,8,9,11,28
.   
Defining direct medical costs:  Direct medical costs were defined as the amount reimbursed by 
Medicare.  Reimbursement rather than charges has been used as a proxy for medical care costs in 
previous cost studies 
8-10
.  Moreover, charges reflect price setting rather than resource 
consumption and hence are not necessarily related to the cost of providing services 
29
.  
Reimbursements are actual payments derived from reimbursement formulas which reflect the 
average resource utilization for each healthcare service 
29
.  Apart from calculating average total 
direct medical costs, costs by type of specific services such as inpatient services, outpatient 
104 
 
services, physician services, and other services were also calculated separately for both the study 
cohorts to identify which Medicare component contributes substantially to the average total costs 
of care.  To account for variation in the costs of medical care services over time, consumer price 
indices (CPI) for medical care services were utilized to convert costs to 2007 US dollars 
30
 and 
hence all the costs are reported in 2007 US dollars.  The Medicare reimbursement formulae for 
all the services already include geographic factors which may affect geographic variations in the 
costs, and hence the costs were not adjusted for any geographic variations.   
Independent Variables:  To identify the factors associated with healthcare costs in elderly 
Medicare FFS with first primary incident BC, the Andersen behavioral healthcare services 
utilization model was utilized 
31,32
.  Based on this model, the independent variables were grouped 
into predisposing factors, enabling factors, need-related factors, healthcare use factors and 
external healthcare environmental factors (Figure 4.1). 
Predisposing factors comprised of age at BC diagnosis (66-69, 70-74, 75-79, 80 and 
older), and race (white, other), while enabling factors consisted of census tract median household 
income (=<$35,000; >$35,000), and census tract percentage of people age >= 25 years with at 
least 4 years of college education (<15%, >=15%).  Since person-level information on household 
income and education level are not available with both the SEER-Medicare and WV-Medicare 
cohorts, census tract information for these two variables were used in this study.  Need-related 
factors included clinical factors such as stage at diagnosis (insitu, local, regional, distant), grade 
of tumor (well-differentiated, moderately differentiated, poorly differentiated, 
undifferentiated/unknown), estrogen-receptor status (positive, negative, borderline/unknown), 
comorbidity scores and mental conditions (depression and/or anxiety) derived from co-occurring 
chronic conditions during the twelve months before BC diagnosis identified from the Medicare 
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files using the ICD-9-CM diagnosis codes.  BC stage at diagnosis was determined according to 
the SEER Summary staging system which uses all information available in the medical record.  
It is a combination of the most precise clinical and pathological documentation of the extent of 
disease 
33
.  Comorbidity scores were calculated using Charlson comorbidity index with macros 
provided by the National Cancer Institute 
34-36
 and were categorized as 0 (no comorbidity), 1, 2+.  
Mental conditions included depression and/or anxiety and was dichotomized as presence or 
absence of a mental condition.  Factors associated with healthcare use were the number of PCP 
visits in the 12 months prior to the BC diagnosis, type of initial treatment in the year subsequent 
to BC diagnosis, and inpatient use.  Similar to previous research, PCP visits were derived from 
the National Claims History (NCH) files using the Medicare provider specialty field found in 
NCH claims and the PCP included those in general practice (01), family practice (08), internal 
medicine (11), geriatric medicine (38), and multi-specialty group practice (70) 
37
.  The PCP visits 
were categorized into two groups (high or low) based on the median value.  Type of initial 
treatment was categorized as definitive surgery only, non-surgical treatment (chemotherapy or 
radiation therapy or both), definitive surgery plus non-surgical therapy, and no treatment.  
Claims related to surgical procedures, chemotherapy, radiation therapy were identified from the 
appropriate Medicare files using a combination of ICD-9-CM diagnosis and procedure codes, 
CPT codes, HCPCS codes and revenue center codes.  Inpatient use during the 12 months after 
BC diagnosis was derived from the inpatient claims file and was dichotomized as presence or 
absence of inpatient use.  External healthcare environmental factors included location of 
residence based on US Department of Agriculture rural-urban continuum codes (metro, non-
metro) and ARF-derived number of hospitals offering oncology-related services in the area of 
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residence.  The hospitals offering oncology-related services were categorized into two groups 
(high or low) based on the median value.   
Statistical Analyses   
 
Descriptive statistics and chi-square statistics were used to describe the characteristics 
and the significant differences in characteristics between the two study cohorts.  CPI adjusted 
average total direct medical costs during the initial period after BC diagnosis and average total 
costs by types of specific services were estimated for both the study populations and were 
statistically compared using t-tests and ratio-of-means.  Ratio-of-means is obtained by dividing 
average total costs of WV-Medicare cohort by average total costs of SEER-Medicare cohort.  In 
addition, average total costs by type of specific services among users of the respective services 
were determined and reported.  Adjusted average total direct medical costs were estimated for 
clinically relevant variables such as stage at BC diagnosis, type of initial treatment and 
comorbidity scores for both the study populations and their ratio-of-means were reported.  Data 
on adjusted average total costs and average costs by types of specific services for both WV-
Medicare and SEER-Medicare cohorts were positively skewed and with high kurtosis (>3).  
Hence transformation of these costs data was required.  Breusch-Pagan/Cook-Weisberg test and 
simplified White test were performed to check for heteroscedasticity and kurtosis of log-scale 
residuals in the costs data 
38
.  Due to presence of distributional problems such as skewness, 
kurtosis of log-scale residuals and heteroscedasticity, Park tests 
39
 were conducted for total costs, 
and for costs by types of specific service for both the study populations to determine the most 
appropriate model which may produce the most precise estimates for the costs data.  The results 
of the Park tests suggested that Generalized Linear Model (GLM) with log link function and 
gamma distribution was the most appropriate regression to model costs in this study. 
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GLM regressions with log transformation for adjusted total costs and gamma distribution 
as the link function were conducted separately for both the study populations to determine the 
predictors of total healthcare costs incurred during the initial period after BC diagnosis in elderly 
women, after controlling for all the independent variables.  GLM regressions were also 
conducted on total, inpatient, outpatient, and physician services costs after controlling for setting 
(WV-Medicare vs. SEER-Medicare) and other independent variables, to determine the 
significant differences between total costs and costs by services between WV-Medicare and 
SEER-Medicare cohorts.  The independent variables, predisposing factors, enabling factors, 
need-related factors, factors affecting healthcare use and external environmental healthcare 
access factors were entered in sequential blocks in the regression models.  Model 1 included only 
‘type of setting (WV-Medicare vs SEER-Medicare)’ as an independent variable.  Model 2 added 
predisposing and enabling factors in addition to setting variable.  Model 3 added need-related 
factors and factors affecting healthcare use in addition to the variables specified in Model 2.  
Model 4 included external healthcare environmental factors in addition to the variables specified 
in Model 3.  From the GLM regressions, the parameter estimates (beta coefficients), betas 
transformed into corresponding average costs, and standard errors were examined.  The findings 
that were significant with p-values less than or equal to 0.05 levels were discussed.  All analyses 
were conducted within statistical analysis system software SAS 9.3 (SAS
®
 version 9.3, SAS 
Institute Inc., Cary, NC, USA) and Stata 13 (StataCorp.2013.Stata Statistical Software:Release 
13.College Station,TX:StataCorp LP).  
Blinder-Oaxaca Decomposition Technique 
To determine the extent to which independent variables explained the differences in total 
average costs in the initial year between WV-Medicare and SEER-Medicare, a post-regression 
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linear decomposition technique was utilized 
23,24
.  This technique helps in examining the 
proportion of total setting difference (WV-Medicare vs SEER-Medicare) being explained by 
different independent variables included in the model, and also in identifying how much of the 
setting differences in total average costs were explained by these independent variables.  The 
decomposition method utilizes the parameter estimates (beta coefficients) from the regressions 
and the means of independent variables to generate two components: ‘explained’ component 
(also known as characteristics effect) which provides differences in the total costs due to 
differences in observed characteristics between WV and SEER-Medicare, and ‘unexplained’ 
component (also known as coefficients effect) which provides differences in the total costs 
between WV-Medicare and SEER-Medicare cohorts that could not be explained, either because 
of differences in the regression parameter estimates between the two groups or differences in 
unobservable or unmeasured independent variables (e.g. provider level, organizational level 
variables) which were not captured and included in the model. 
The explained portion was calculated by multiplying the differences in the average 
characteristics between the WV-Medicare and SEER-Medicare cohorts with the pooled 
regression weights.  The pooled regression weights are the coefficients of the characteristics 
from the regression model which used data from the WV-Medicare and SEER-Medicare cohorts.  




Description of the Study Cohorts 
 
 Table 4.1 describes the WV-Medicare and SEER-Medicare cohorts age 66 and above, 
diagnosed with the first primary incident BC in 2003-2006.  Twenty-five percent of the women 
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in the WV-Medicare cohort were age 80 and above as compared to 29% in SEER-Medicare 
cohort.  Majority of WV-Medicare cohort (97.6%) was white as compared to 89% from the 
SEER-Medicare cohort.  A higher proportion of WV-Medicare cohort had a household income 
below $35,000 (91%), resided in areas with less than 15% population with some college 
education (51%), had lower PCP visits (51%) and resided in areas with lower number of 
hospitals with oncology services (60%).  However, a majority of the SEER-Medicare cohort 
resided in metro areas (84%), had household income above $35,000 (75%), resided in areas with 
greater than 15% of population with some college education (70%), had lower PCP visits (54%), 
and resided in areas with a lower number of hospitals with oncology services (55%). 
Average Total Costs and Average Costs by Types of Services 
 Table 4.3 describes the CPI adjusted total average costs and average costs by types of 
specific services during the initial phase of care for both the WV-Medicare and SEER-Medicare 
cohorts, and also presents the ratio-of-means between the WV-Medicare and SEER-Medicare 
cohorts.  The average total costs for WV-Medicare cohort during initial phase of care was 
$19,875 (SE=483), while the average total costs for those belonging to the SEER-Medicare 
cohort was $22,881 (SE=100).  The ratio-of-means was 0.87 and the total average costs for the 
WV-Medicare cohort was significantly lower than that of the SEER-Medicare cohort.  Total 
average inpatient costs for WV-Medicare cohort $4,707 (SE=255) was also significantly lower 
than the costs for SEER-Medicare cohort $5,254 (SE=59) with ratio-of-means of 0.90.  The total 
average outpatient costs for the WV-Medicare cohort and the SEER-Medicare cohort were 
$5,767 (SE=237) and $5,806 (SE=34) respectively, with ratio-of-means 0.99.  The total average 
costs for physician services were significantly lower for the WV-Medicare cohort ($8,684, 
SE=261) as compared to the SEER-Medicare cohort ($10,800, SE=57), with ratio-of-means of 
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0.80.  Also the total average costs for other services were significantly lower for the WV-
Medicare cohort ($716, SE=60) as compared to the SEER-Medicare cohort ($1,020, SE=16). 
 Among users of the specific services, total average inpatient costs were significantly 
lower for the WV-Medicare cohort ($9,745) as compared to the SEER-Medicare cohort 
($11,239), and ratio-of-means was 0.87.  The total average costs among users of physician 
services were also significantly lower for the WV-Medicare cohort ($8,684) as compared to the 
SEER-Medicare cohort ($10,814) with a ratio-of-means of 0.80.  
Average Total Costs for Clinically Important Variables 
 Table 4.4 describes the average total costs for clinically important variables such as stage 
at diagnosis, type of initial treatment, and comorbidity score.  Average total costs in the WV-
Medicare women with distant stage at BC diagnosis was $27,073 (SE=3,635) as compared to 
$43,431 (SE=973) in the SEER-Medicare women with distant stage, and the ratio-of-means was 
0.62.  WV-Medicare cohort who had adjuvant therapy only as the initial treatment had average 
total expenditures of $26,498 as compared to $33,786 for the SEER-Medicare cohort, with ratio-
of-means of 0.78.  Average total costs were lower for the WV-Medicare cohort with 2 or more 
comorbidities as compared to the SEER-Medicare cohort with two or comorbidities ($22,018 vs. 
$27,593), with a ratio-of-means of 0.80. 
Factors Associated with Average Total Costs 
 Table 4.5 summarizes the results from the separate GLM regression models on total 
average costs during the initial phase of care in the WV-Medicare and the SEER-Medicare 
cohorts.  In the WV-Medicare cohort, women who had regional or distant stage of BC, who had 
surgery with adjuvant therapy or who had adjuvant therapy only, who had inpatient visits, who 
had two or more comorbidities, and who had either depression or anxiety had significantly 
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higher total average costs.  Also, WV-Medicare cohort who was age 75 or older had significantly 
lower total average costs.  In the SEER-Medicare cohort, women who resided in areas with 
higher education, who were diagnosed at advanced stages of BC, who did not have a well-
differentiated tumor grade, who had negative ER tumor status, who had any kind of treatment in 
form of surgery or adjuvant therapy, who had inpatient visits and PCP visits, and who had any 
comorbidity had significantly higher total average costs.  In addition, the SEER-Medicare cohort 
who was age 70 or older, and who resided in non-metro areas had significantly lower total 
average costs.  The beta estimates and exponentiated average costs for all the independent 
variables within each GLM regression are reported in Table 4.4.   
Differences in Average Total Costs and Average Costs by Types of Services 
 Table 4.6 summarizes the results from the separate multivariate GLM regression models 
on total average costs, average costs for types of specific services during the initial phase of care, 
to identify any significant differences in these costs between WV-Medicare cohort and SEER-
Medicare cohort.  As compared to the SEER-Medicare cohort, total average costs were 
significantly lower for the WV-Medicare cohort.  In Model 1 without adjusting for other 
independent variables, the WV-Medicare cohort had lower total average healthcare costs as 
compared to the SEER-Medicare cohort by $3,006.  However, this difference shrunk to $549 in 
Model 4 after adjusting for all the independent variables.  The total average costs for inpatient 
and physician services were also significantly lower for the WV-Medicare cohort as compared to 





Factors Explaining Lower Average Total Costs in the WV-Medicare Cohort Using Blinder-
Oaxaca Linear Decomposition Analysis 
 Table 4.7 summarizes the results from the Blinder-Oaxaca linear decomposition analysis.  
The total average costs for WV-Medicare cohort for the initial phase of care was $19,875 and 
that for the SEER-Medicare cohort was $22,881, a difference of $3,006 in total average costs 
between these two cohorts.  Using the pooled weights, 15.82% of the difference in the total 
average costs between the two cohorts was explained by the beneficiary characteristics.  
Enabling resources (census tract income and education) contributed 6.85%, healthcare use (PCP 
visits, type of initial treatment, inpatient use) contributed 7.53%, and external healthcare 
environmental factors (location of residence, hospital visits) contributed 3.33% to the total 
explained portion of 15.82%.  Detailed examination of the decomposition results revealed that 
the differences in the type of initial treatment explained 11.52% of the differences in the total 
average costs between the two groups.  This can be interpreted as follows: keeping all the other 
characteristics same, if WV-Medicare cohort had the same course of initial treatment as the 
SEER-Medicare cohort, then the WV-Medicare cohort would have had a lower total average 
costs.  A total of 84.14% of the differences in the total average costs in the initial phase of care 
between WV-Medicare and SEER-Medicare cohorts remained unexplained. 
 Since only 16% of the differences between WV-Medicare and SEER-Medicare cohorts 
were explained by the beneficiary characteristics discussed above, it was hypothesized that other 
factors related to healthcare utilization such as number of radiation visits, number of 
chemotherapy visits, and type of surgeon seen (general surgeon vs. oncology surgeon) may 
explain a portion of lower total average costs in the WV-Medicare cohort.  The post-hoc analyses 
was conducted to evaluate significant differences between the study cohorts for the additional 
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healthcare use factors such as number of radiation visits, number of chemotherapy visits and type 
of surgeon seen by the Medicare beneficiaries and its results are reported in Table 4.2.   A higher 
proportion of the WV-Medicare cohort had no radiation visits as compared to the SEER-
Medicare cohort (51% vs. 47%).  However, among those who had radiation visits, WV-Medicare 
cohort had higher proportion of women with at least 10 radiation visits in the year following BC 
diagnosis as compared to the SEER-Medicare cohort.  There were no significant differences 
between the two study cohorts for number of chemotherapy visits and type of surgeon seen in the 
year following BC diagnosis.  Another post-hoc Blinder-Oaxaca decomposition analyses was 
also conducted to identify the extent to which the previously included independent variables and 
the additional healthcare use factors explained the magnitude of differences in these study 
cohorts.  Using the pooled weights, only 11% of the difference in the total average costs between 
the two cohorts was explained by the beneficiary characteristics (data not shown).  Healthcare 
use contributed 61%, enabling resources contributed 28% and external healthcare environmental 
factors contributed 29% to the total explained portion (data not shown).   
DISCUSSION 
 As the costs of BC constitute a substantial portion of the overall national costs of cancer 
care and as these costs are likely to increase tremendously in the coming years 
3
, estimating the 
BC costs and the costs by types of specific services is vital for the Medicare program to focus on 
controlling these costs and setting priorities for the effective allocation of the resources.  
Previous studies which estimated total average costs in the initial phase of care in BC patients 
have been outdated and utilized data from SEER-Medicare registries only 
3,6,7,10
.  This study is 
first of its kind to identify costs by types of specific services and the factors associated with 
higher costs in BC patients, from a non-SEER-Medicare and rural geographic region and 
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compared it with the national estimates derived from SEER-Medicare data, and to examine the 
which factors explained the differences in the average costs between the WV-Medicare and 
SEER-Medicare cohorts.  The study findings indicate that the two populations were statistically 
different in terms of most of their characteristics.  The total average costs, and the average costs 
for inpatient services, physician services and other services in the initial phase of care in elderly 
BC patients from WV-Medicare cohort was significantly lower than that for the SEER-Medicare 
cohort.  The total average costs, average costs for inpatient services and physician services were 
13%, 13% and 20% higher, respectively, for SEER-Medicare cohort than for WV-Medicare 
cohort as seen in Table 2.  These findings did not change even after controlling for the 
comprehensive list of covariates in the multivariate framework.  A part of the lower costs in a 
rural state such as WV as compared to the SEER-Medicare regions may be due to the differences 
in the Medicare spending across various geographic regions in the US 
40
.   In addition, average 
costs by stage at diagnosis, type of initial treatment, and comorbidity scores were also lower for 
the BC patients in WV than that for the SEER-Medicare elderly women.   
 In contrast to study by Warren et al., it was found that physician services was the major 
contributor to the total average costs in the initial phase of care among the elderly WV-Medicare 
and SEER-Medicare beneficiaries with BC 
10
, followed by outpatient costs and inpatient costs.  
Average costs for physician services, inpatient services, and outpatient services were lower for 
WV-Medicare cohort as compared to their national counterparts.  Among users of specific 
services, average costs due to inpatient services was the highest for both the groups, followed by 
average costs due to physician services.  However, these costs were lower for WV-Medicare 
cohort as compared to their national counterparts.  These findings are surprising given the fact 
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that elderly WV women with BC have higher comorbidity burden and possibly greater 
proportion of negative health-outcomes which may increase their total average costs.   
 In elderly WV women with BC, the factors associated with higher costs during the initial 
phase of care were advanced stages of the cancer, surgery with adjuvant therapy or adjuvant 
therapy only, any hospitalization, presence of two or more physical chronic conditions, and 
presence of depression and/or anxiety.  But older age was associated with lower average costs in 
these women.  These findings were consistent with those reported in the previous study on 
Virginia population 
11
.  These findings highlight the importance of encouraging women to utilize 
preventive screenings to get them diagnosed at earlier stages of BC.  In addition, the findings 
also emphasize the importance of better co-management of physical and mental chronic 
conditions in elderly women with BC, to lower overall costs to Medicare in a rural state such as 
WV.  Emerging healthcare delivery models such as ‘medical homes’ which emphasize care-
coordination for management of the elderly Medicare beneficiaries with multiple chronic 
conditions are a step in the right direction. 
 The differences in the total average costs for elderly women with BC were also examined 
between the two cohorts in a multivariable setting.  There were statistically significant difference 
in the total average costs between the two groups after controlling for the predisposing, enabling, 
need-related, healthcare use, and external healthcare environmental factors.  The difference in 
total average costs in the initial phase of care reduced from $3,006 to $549 after adjusting for all 
the covariates.   
The study also utilized the unique Blinder-Oaxaca linear decomposition technique to 
examine the extent to which the differences in the various factors explained the difference in the 
total average costs between the two cohorts.  Enabling resources (household income and 
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education), and healthcare use (PCP visits, type of initial treatment, inpatient use) primarily 
explained the differences in the total average costs between the two populations.  These findings 
are consistent to the findings from previous studies which reported that the differences in 
healthcare spending is largely explained by the differential treatment pattern owing to the supply 
of physicians and hospital resources in the area, and also household income and education 
41-44
.  
Hence, if both the study populations have similar household income and education, PCP visits, 
initial treatment and inpatient use then the difference in the total average costs would shrink.  A 
noteworthy finding of this study is that around 84% of the difference in total average 
expenditures between the two populations remained unexplained.  It is plausible that some 
portion of this difference may be due to unmeasured factors such as health status, severity of 
comorbid conditions, body mass index, patient preferences and propensity to seek care.  The 
results of the post-hoc decomposition analyses after adding additional healthcare use factors such 
as number of radiation visits, number of chemotherapy visits and type of surgeon seen by the 
beneficiaries did not increase the ‘explained’ portion of the differences in the total average costs 
between the two study cohorts.  Hence, healthcare utilization may not be a contributing factor for 
lower total average costs in the initial phase for the WV-Medicare cohort as compared to the 
national averages.   
 Since the analyses of the costs for BC utilized the data from administrative claims, the 
results of this study should be interpreted with caution.  Any healthcare services obtained outside 
of Medicare settings may not be captured, hence the costs may be underestimated.  The costs of 
adjuvant therapy with prescription drugs were not captured in the analyses as these costs were 
not covered by Medicare prior to 2007.  Also, indirect medical costs (e.g. cost due to lost 
productivity), indirect non-medical costs, and out-of-pocket costs borne by patients were not 
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included and hence the findings do not represent the total costs during the initial phase of care.  
Certain patient characteristics such as annual household income, education level, access to total 
of BC screening centers at patient level are not available in the cancer registries-Medicare linked 
databases and hence census tract information for these variables have been utilized 
45
.  Data on 
some important variables such as health status, severity of comorbidities, and patient preferences 
which may be important predictors of their cancer prognosis, or selection of type of treatment 
were not available.  Moreover, the findings of this study are generalizable to elderly BC patients 
only covered by Medicare.  Also the findings are not generalizable to other rural populations.  
Costs may vary in a younger population due to differences in their age and insurance coverage. 
CONCLUSION 
 The difference in the total average expenditures between the elderly beneficiaries with 
BC from a rural state such as WV and their national counterparts narrowed but remained 
significantly lower after multivariate adjustment, and is mainly driven by enabling factors and 
healthcare use factors.  Further research focusing on the incremental costs among elderly 
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Description of the Study Cohorts 
2003-2006 




(N=39,525)   
    N % N % Sig 
Age at Diagnosis 
    
*** 
 
66-69 275 19.8 8,799 22.3 
 
 
70-74 384 27.7 9,868 25.0 
 
 
75-79 379 27.3 9,331 23.6 
 
 
80,+ 349 25.2 11,527 29.2 
 Race 
    
*** 
 
White 1,354 97.6 34,992 88.5 
 
 
Other 33 2.4 4,533 11.5 
 Location of Residence 
    
*** 
 
Metro 761 54.9 32,989 83.5 
 
 
Non-metro 626 45.1 6,536 16.5 
 Census Tract Household Income 
   
*** 
 
LE $35,000 1,267 91.4 9,764 24.7 
 
 
GT $35,000 120 8.6 29,761 75.3 
 Census Tract Education 
    
*** 
 
LT 15% pop. with CE 703 50.7 12,056 30.5 
 
 
GE 15% pop. with CE 684 49.3 27,469 69.5 
 Stage at Diagnosis 
    
** 
 
Insitu 209 15.1 6,610 16.7 
 
 
Local 866 62.5 22,738 57.5 
 
 
Regional 273 19.7 8,985 22.7 
 
 
Distant 39 2.7 1,192 3.0 
 Grade of Tumor 
    
*** 
 
Well Differentiated 325 23.4 8,459 21.4 
 
 
Moderately Differentiated 472 34.0 15,524 39.3 
 
 
Poorly Differentiated 306 22.1 9,969 25.2 
 
 
Undifferentiated/Unknown 284 20.5 5,573 14.1 
 ER Status 
    
*** 
 
Positive 627 45.2 27,260 69.0 
 
 
Negative 126 9.1 5,412 13.7 
 
 
Borderline/Unknown 634 45.7 6,853 17.3 
 Initial Treatment 
    
** 
 
Surgery Only 560 40.4 14,478 36.6 
 
 
Surgery+Adjuvant Therapy 765 55.2 23,494 59.4 
 
 
Adjuvant Therapy Only 16 1.2 581 1.5 
 
 
No Treatment 46 3.3 972 2.5 
 Inpatient Use 
     
 
Yes 681 49.1 18,621 47.1 
 
 
No 706 50.9 20,904 52.9 
 Comorbidity 
    
*** 
 
1-10 conditions 715 51.6 23,039 58.3 
 
 
11 to 20 conditions 416 30.0 10,629 26.9 
 
 
>20 conditions 256 18.4 5,857 14.8 
 Mental Condition 
    
*** 
 
Yes 134 9.7 2,411 6.1 
 
 
No 1,253 90.3 37,114 93.9 




Description of the Study Cohorts 
2003-2006 




(N=39,525)   
    N % N % Sig 
PCP visits 
    
* 
 
High 681 49.1 18,051 45.7 
 
 
Low 706 50.9 21,474 54.3 




High 551 39.7 17,613 44.6 
 
 
Low 836 60.3 21,912 55.4 
               
 
Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 
Results; ER, Estrogen-receptor; PCP, Primary Care Physicians; CE, College Education; pop., population; LE, Less than or equal 
to; GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent statistically significant 





Description of the Study Cohorts for Differences in the Healthcare Utilization 
2003-2006 




(N=39,525)   
    N % N % Sig 
Radiation Visits 
    
*** 
 
No visit 700 50.5 18,475 46.7 
 
 
Low visits (1-10) 201 14.5 11,563 29.3 
 
 
High visits (10,+) 486 35.0 9,487 24.0 
 Chemotherapy Visits 
     
 
No 1,084 78.2 30,545 77.3 
 
 
Yes 303 21.8 8,980 22.7 
 Type of Surgeon Seen 
     
 
No surgeon seen 31 2.2 752 1.9 
  General Surgeon 355 25.6 9,287 23.5  
 Oncology Surgeon 73 5.3 2,320 5.9  
 
Both 928 66.9 27,166 68.7 
              
 
Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 
Results; Sig, Significance. Asterisks represent statistically significant group differences based on χ2 tests: ***P<0.001; 
















Average Total Healthcare Costs and Average Healthcare Costs by Type of Service  
For the Study Cohorts 
2003-2006 
  Among All Users 
  
WV-Medicare (N=1,387) SEER-Medicare (N=39,525) 
Ratio-of-
Means 
  Average ($) SE % Average ($) SE %   
Total*** 19,875 483 100% 22,881 100 100% 0.87 
Inpatient* 4,707 255 24% 5,254 59 23% 0.90 
Outpatient 5,767 237 29% 5,806 34 25% 0.99 
Physician Services*** 8,684 261 44% 10,800 57 47% 0.80 
Other (HHA, HSP, DME)*** 716 60 4% 1,020 16 4% 0.70 
                
  Among Users of Specific Services   
  WV-Medicare SEER-Medicare   
  N Average ($) SE N Average ($) SE   
Inpatient* 670 9,745 454 18,479 11,239 111 
 
Outpatient 1,372 5,830 239 38,531 5,956 34 
 
Physician Services*** 1,387 8,684 261 39,474 10,814 57 
 
Other (HHA, HSP, DME)*** 727 1,366 110 19,579 2,060 31 
                 
 
Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 
Results; CPI, Consumer Price Index; HHA, Home Health Agency; HSP, Hospice; DME, Durable Medical Equipment; SE, 
Standard Error. Asterisks represent statistically significant group differences based on t-tests: ***P<0.001; **001<=P<.01 ; 
























Average Total Healthcare Costs for Clinically Important Variables For the Study Cohorts 
2003-2006 
    Among All Users 
    WV-Medicare SEER-Medicare Ratio-of-Means 
    N 
Average 
costs ($) SE N 
Average 
costs ($) SE   
Stage at Diagnosis 
       
 
Insitu 209 13,148 871 6,610 14,872 169 0.88 
 
Local 866 17,484 514 22,738 20,124 107 0.87 
 
Regional 273 31,592 1,401 8,985 33,024 255 0.96 
 
Distant 39 27,073 3,635 1,192 43,431 973 0.62 
Initial Treatment 
       
 
Surgery Only 560 12,306 593 14,478 15,119 137 0.81 
 
Surgery+Adjuvant Therapy 765 25,664 660 23,494 27,774 129 0.92 
 
Adjuvant Therapy Only 16 26,498 3,832 581 33,786 1,254 0.78 
 
No Treatment 46 13,422 3,160 972 13,699 751 0.98 
Comorbidity 
       
 
0 715 18,432 625 23,039 21,438 119 0.86 
 
1 416 21,034 954 10,629 23,412 199 0.90 
 
2,+ 256 22,018 1,171 5,857 27,593 324 0.80 
                  
 
Note: Based on 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above diagnosed 
with primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End 



















Factors Associated with Average Total Healthcare Costs Separately for the Study Cohorts 
Using Generalized Linear Model Regressions  
2003-2006 
Variables   WV-Medicare (N=1,387) SEER-Medicare (N=39,525) 
    Beta 
Average 
costs ($) SE Sig Beta 
Average 
costs ($) SE Sig 
          Intercept (Baseline Costs) 8.6015 5,440 0.1342 *** 8.6028 5,447 0.0252 *** 
Age at Diagnosis 
        
 
66-69 
        
 
70-74 -0.0666 5,089 0.0503 
 
-0.0349 5,260 0.0086 *** 
 
75-79 -0.1678 4,599 0.0507 *** -0.0836 5,010 0.0088 *** 
 
80,+ -0.1121 4,863 0.0538 * -0.1376 4,747 0.0088 *** 
Race 
         
 
White 
        
 
Other -0.0233 5,315 0.1120 
 
-0.0096 5,395 0.0096 
 
Location of Residence 
        
 
Metro 
        
 
Non-metro -0.0762 5,041 0.0440 
 
-0.0814 5,021 0.0092 *** 
Census Tract Household Income 
       
 
LE $35,000 
        
 
GT $35,000 0.0208 5,554 0.0755 
 
0.0150 5,529 0.0084 
 
Census Tract Education 
       
 
LT 15% pop. with CE  
     
 
GE 15% pop. with CE -0.0075 5,399 0.0477 
 
0.0285 5,604 0.0076 *** 
Stage at Diagnosis 
        
 
Insitu 
        
 
Local 0.0940 5,976 0.0508 
 
0.1625 6,408 0.0091 *** 
 
Regional 0.4257 8,327 0.0617 *** 0.4081 8,192 0.0106 *** 
 
Distant 0.5909 9,822 0.1220 *** 0.7389 11,404 0.0203 *** 
Grade of Tumor 
        
 
Well Differentiated 
       
 
Moderately Differentiated -0.0061 5,407 0.0462 
 
0.0282 5,603 0.0080 *** 
 
Poorly Differentiated 0.0118 5,504 0.0538 
 
0.0977 6,006 0.0093 *** 
 
Undifferentiated/Unknown -0.0504 5,172 0.0539 
 
0.0365 5,649 0.0108 *** 
ER Status 
        
 
Positive 
        
 
Negative 0.1061 6,049 0.0649 
 
0.0976 6,005 0.0094 *** 
 
Borderline/Unknown -0.0402 5,225 0.0369 
 




       (Continued)… 
 




Factors Associated with Average Total Healthcare Costs Separately for the Study Cohorts 
Using Generalized Linear Model Regressions  
2003-2006 
Variables   WV-Medicare (N=1,387) SEER-Medicare (N=39,525) 
    Beta 
Average 
costs ($) SE Sig Beta 
Average 
costs ($) SE Sig 
Initial Treatment 
 
Surgery Only 0.1165 6,112 0.1040 
 
0.1843 6,549 0.0201 *** 
 
Surgery+Adjuvant Therapy 1.0199 15,084 0.1051 *** 0.9223 13,699 0.0202 *** 
 
Adjuvant Therapy Only 0.7929 12,021 0.1867 *** 0.7776 11,854 0.0317 *** 
 
No Treatment 
       
Inpatient Use 
        
 
Yes 0.7829 11,901 0.0370 *** 0.7065 11,040 0.0065 *** 
 
No 
        
Comorbidity 
        
 
0 
        
 
1 0.0726 5,849 0.0395 
 
0.0668 5,823 0.0070 *** 
 
2,+ 0.1904 6,581 0.0478 *** 0.2105 6,723 0.0090 *** 
Mental Condition 
        
 
Yes 0.2480 6,971 0.0581 *** 0.0841 5,925 0.0125 *** 
 
No 
        
PCP visits 
        
 
High 0.0138 5,515 0.0353 
 
0.0786 5,892 0.0062 *** 
 
Low 
        
Total Hospitals with Oncology Services 
      
 
High 0.0654 5,807 0.0498 
 
0.0738 5,864 0.0066 *** 
 
Low 
        
                    
 
Note: Based on average costs in initial phase of care, in 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare 
women, age 66 and above from 2003 to 2006 diagnosed with first primary incident breast cancer from 2003 to 2006.  FFS, Fee-
for-service; WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CPI, Consumer Price Index; SE, Standard 
Error; ER, Estrogen-receptor; PCP, Primary Care Physicians; CE, College Education; pop., population; LE, Less than or equal to; 
GT, Greater than; LT, Less than; GE, Greater than or equal to; Sig, Significance. Asterisks represent statistically significant 
group differences based on Generalized Linear Model with gamma distribution and log link function: ***P<0.001; 




Differences in Average Total Costs between the Study Cohorts 
Using Generalized Linear Model Regressions  
2003-2006 
    Model 1 Model 2 Model 3 Model 4 
    Beta 
Average 
costs ($) SE Sig Beta 
Average 
costs ($) SE Sig Beta 
Average 
costs ($) SE Sig Beta 
Average 
costs ($) SE Sig 
Total Costs 
                
 
Intercept 10.0381 22,882 0.0039 *** 10.1151 24,713 0.0111 *** 8.5944 5,401 0.0244 *** 8.6060 5,464 0.0248 *** 
 
WV-Medicare -0.1410 19,873 0.0210 *** -0.1107 22,124 0.0218 *** -0.1029 4,873 0.0170 *** -0.1059 4,915 0.0170 *** 
 
SEER-Medicare 
                
Inpatient Costs 
                
 
Intercept 9.3271 11,238 0.0065 *** 9.1568 9,479 0.0187 *** 9.6841 16,060 0.4973 *** 9.7625 17,370 0.4948 *** 
 
WV-Medicare -0.1436 9,735 0.0349 *** -0.0819 8,733 0.0361 * -0.0915 14,656 0.0353 ** -0.0917 15,848 0.0351 ** 
 
SEER-Medicare 
                
Outpatient Costs 
                
 
Intercept 8.6922 5,956 0.0051 *** 8.7953 6,603 0.0145 *** 7.3029 1,485 0.0374 *** 7.2181 1,364 0.0380 *** 
 
WV-Medicare -0.0209 5,833 0.0275 
 
0.0092 6,664 0.0284 
 




                
Physician Services Costs 
               
 
Intercept 9.2886 10,814 0.0042 *** 9.4193 12,324 0.0116 *** 7.5664 1,932 0.0262 *** 7.6349 2,069 0.0266 *** 
 
WV-Medicare -0.2191 8,686 0.0228 *** -0.1406 10,708 0.0230 *** -0.1531 1,658 0.0183 *** -0.1377 1,803 0.0183 *** 
 
SEER-Medicare 
                 
Note: Based on average costs in initial phase of care, in 1,387 elderly WV-Medicare women and 39,525 elderly SEER-Medicare women, age 66 and above from 2003 to 2006 
diagnosed with first primary incident breast cancer from 2003 to 2006.  WV, West Virginia; SEER, Surveillance, Epidemiology, and End Results; CPI, Consumer Price Index; SE, 
Standard Error; Sig, Significance. Asterisks represent statistically significant group differences based on Generalized Linear Model with gamma distribution and log link function: 
***P<0.001; **001<=P<.01 ; *.01<=P<.05.   
Model 1 includes only WV-Medicare/SEER-Medicare groups and no other independent variables 
Model 2 includes WV-Medicare/SEER-Medicare groups, and adjusts for predisposing (age, race) and enabling (census tract income and education) as independent variables 
Model 3 includes WV-Medicare/SEER-Medicare groups, and adjusts for predisposing (age, race), enabling (census tract income and education), need-related (stage at diagnosis, 
grade of tumor, estrogen receptor status, comorbidities, mental conditions) and healthcare use (Primary care physician visits, type of initial treatment, inpatient use) as independent 
variables 
Model 4 includes WV-Medicare/SEER-Medicare groups, and adjusts for the independent variables listed above in addition to external healthcare environmental factors (location of 




Factors Explaining Lower Total Average Costs in WV-Medicare Cohort 
Using Blinder-Oaxaca Linear Decomposition Analysis 
2003-2006 




% Contribution to the 
‘Explained’ Portion 
Predisposing characteristics (Age, Race) -0.40% -2.53% 
Enabling resources (Census tract Annual Household Income and 
Education) 
6.85% 43.30% 
Need-Related Variables (Stage at Diagnosis, Grade of Tumor, ER 
status, Comorbidity, Mental Conditions) 
-1.50% -9.48% 
Healthcare Use (PCP visits, Type of Initial Treatment, Inpatient 
use) 
7.53% 47.60% 
External Healthcare Environmental Factors (Location of Residence, 
Number of Hospitals with Oncology Services) 
3.33% 21.05% 
Total Difference Explained 15.82% 100.00% 




















































































SUMMARY AND CONCLUSIONS 
 
RATIONALE AND OBJECTIVES 
Breast cancer (BC) is the most common cancer among women and is the second leading 
cause of cancer death in women in the United States (US).  Based on 2005-2009 Surveillance, 
Epidemiology and End Results (SEER) statistics, 41% of the new BC cases and 57.4% of the BC 
deaths occur in women age 65 and above 
1
.  The overall incidence of BC in women below 65 
years of age is 82.97 per 100,000 women and is 421.30 per 100,000 women in those above age 
65 
1
.  The overall mortality from BC is 11.15 per 100,000 women for those less than 65 years of 
age and is 98.64 per 100,000 women in those above age 65 
1
.  Besides, elderly women age 65 
and above have a greater burden of BC as they are diagnosed at more advanced stages and with 
larger tumors impacting their survival 
2
. 
In a rural state such as WV which is medically underserved with rates of chronic disease 
and poor health behaviors 
3-6
, rates of advanced and unstaged BC are high 
7-11
 owing to lower 
mammography screening rates in women in this state 
8-12
.  Also, WV have lower incidence of BC 
(372.8 per 100,000 vs. 411.7 per 100,000) but higher BC-related mortality (110.4 per 100,000 vs. 
98.6 per 100,000) as compared to the national estimates 
13,14
.  These may be because of low 
mammography screening rates 
9-11,15
, limited physical access to services, shortage of healthcare 
professionals and services 
16
, and untimely BC care.  These disparities also indicate that elderly 
women diagnosed with BC in WV may have higher healthcare costs after cancer diagnosis.   
There is no clear evidence about the beneficial effects of mammography screening in 
elderly women age 65 and above due to lack of inclusion of these women in clinical trials 
17
 and 
discrepancy about evidence-based guidelines for mammography screening in these women.  
133 
 
Previous published studies which reported benefits of mammography screening on representation 
of stage of BC in elderly women have been limited in terms of including women of certain age 
groups only, utilizing data from fewer cancer registries, not capturing persistent mammography 
utilization before BC diagnosis, and not distinguishing screening from diagnostic mammography 
claims which is an inherent issue with Medicare claims data 
18-21
.  Moreover, very limited 
information is available about the association between mammography screening and stage of 
disease in elderly Medicare beneficiaries with BC from a rural setting and from non-SEER-
Medicare states.   
Although timely care in BC patients is highly crucial, the US-based guidelines have not 
yet defined an appropriate time frame for diagnosis and treatment.  Previous published studies on 
timeliness of BC care 
22-30
 have no consensus in regards to an appropriate time for diagnosis and 
treatment.  Also none of these studies have followed any published opinion-based guidelines to 
appropriately define timely diagnosis and treatment.  With lower incidence of BC but higher BC-
related mortality in elderly women in WV as compared to national estimates, it is highly likely 
that timeliness of BC care may be one of the important contributors to these disparities.   
Female BC comprises the highest proportion of national cancer care costs which is 
expected to increase by 32% in 2020 
31
.  In addition, BC has the highest costs in the initial phase 
of care (one year after diagnosis) among all the cancers 
31
.  A systematic review on BC costs in 
the US suggested that majority of the studies included in the review were outdated and/or 
focused on women with selected stages only 
32
.  Few recent studies on costs have utilized data 
only till 2003 and from fewer cancer registries 
31,33-35
.  Moreover, very limited information is 
available about BC costs from a rural setting and from non-SEER states. 
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To address these gaps in the literature and to identify the factors associated with higher 
BC-mortality in the elderly WV women, a series of retrospective observational cohort studies 
were conducted using data from the elderly fee-for-service (FFS) Medicare beneficiaries with 
first incident primary BC from the West Virginia Cancer Registry (WVCR)-Medicare linked 
dataset and the results were compared with national estimates derived from the SEER-Medicare 
linked dataset.  In study one, the proportion of Medicare FFS beneficiaries in WV with incident 
BC persistent with mammography screening and the association between persistence with 
mammography screening and stage at BC diagnosis in a multivariate framework was determined 
and compared with the national estimates derived from the SEER-Medicare dataset.  In study 
two, timeliness of BC care in terms of timely diagnosis and timely treatment based on published 
opinion-based guidelines, factors associated with timeliness and the effect of timely care on the 
probability of being alive were examined in elderly WV women with BC and compared with the 
national estimates derived from the SEER-Medicare dataset.  In study three, total average 
healthcare utilization and costs in the initial period of one year after BC diagnosis and average 
utilization and costs by types of services and the factors associated with higher healthcare costs 
in initial period were evaluated in elderly WV women and these estimates were compared with 
the national estimates derived from the SEER-Medicare dataset. 
SUMMARY OF FINDINGS 
 Overall, the study findings indicated that the elderly FFS Medicare beneficiaries with 
first primary incident BC from WV were statistically different from the nationally representative 
population from SEER-Medicare.  The WV-Medicare study cohort was relatively younger, 
predominantly white, lived in non-metro areas, with lower median household income and mainly 
belonged to the areas with lower percentage of people with college education as compared to the 
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SEER-Medicare cohort.  In addition, the WV-Medicare cohort was mostly diagnosed at local 
stage of BC, had higher primary care physicians (PCP) visits, and had two or more comorbid 
chronic conditions. 
Persistence with Mammography Screening and Stage at Diagnosis among Elderly Women 
Diagnosed with Breast Cancer 
 In the retrospective observational cohort study, 51% of women in WV-Medicare cohort 
were persistent with mammography screening as compared to 45.4% in the SEER-Medicare 
cohort.  In the WV-Medicare cohort, of those not persistent with mammography screening, 31% 
were diagnosed with late stage BC while among those who were persistent with mammography 
screening, only 12% were diagnosed with late stage BC.  However, in the SEER-Medicare 
cohort, of those not persistent with mammography screening, 39% were diagnosed with late 
stage BC while 17% were diagnosed with late stage BC among those who were persistent with 
mammography screening.  In the multivariate framework for the WV study cohort, persistence 
with mammography screening was significantly associated with early stage BC.  While for the 
SEER-Medicare cohort, persistence with mammography screening, higher household income 
and higher PCP visits were significantly associated with earlier stage at BC diagnosis.  This 
study also showed that elderly FFS Medicare beneficiaries with BC in WV were equally likely to 
be diagnosed at an early stage of BC as compared to their national counterparts from SEER-
Medicare after controlling for persistence with mammography screening.  The study findings 
contradict reports of lower mammography utilization in WV 
8,9,12,36
 as the contributor of late 
stage BC leading to higher BC-related mortality.  This also indicates that there may be other 
factors such as poor health status, family history of BC, BRCA gene mutation, untimely or 
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inappropriate care that may be responsible for higher rates of late stage BC in elderly women in 
WV, which affect their survival. 
Timeliness of Care among Elderly Women Diagnosed with Breast Cancer  
In this retrospective observational cohort study, the median days from initial consultation 
for abnormality to BC diagnosis was 26 (Interquartile Range (IQR)=12-50 days) for the WV-
Medicare cohort as compared to 20 (IQR=8 to 41 days) for the SEER-Medicare cohort.  The 
overall median days from BC diagnosis to any BC treatment was 8 (IQR=0-28 days) for the WV-
Medicare cohort as compared to 15 (IQR=0-29 days) for the SEER-Medicare cohort.  
Approximately, only 63% of women in the WV-Medicare cohort received timely diagnosis of 
BC (i.e. consistent with the published opinion-based EUSOMA recommendations) as compared 
to 71% of the SEER-Medicare cohort.  Also, 76% of the WV-Medicare cohort received timely 
BC treatment (i.e. consistent with the published opinion-based NICE recommendations) as 
compared to 73% from the SEER-Medicare cohort.  For the WV-Medicare cohort, census tract 
household income above $35,000 and tumor size > 3 cm was significantly associated with timely 
diagnosis of BC; however, no factors were significantly associated with timely treatment of BC.  
In addition, the WV-Medicare cohort was significantly less likely to receive timely diagnosis of 
BC but it was equally likely as the SEER-Medicare cohort to receive timely treatment for BC.  
Furthermore, the WV-Medicare cohort was significantly more likely to be alive at the follow-up 
period of three years as compared to the SEER-Medicare cohort.  It is possible that other factors 
such as WV women’s social and cultural barriers including fear, sense of fatalism, knowledge 
and beliefs, perceived risk, physicians’ characteristics, and health system factors 
24,37-43
 which are 
not measured in this study may be contributing to the higher BC-mortality rate among WV 
women.  The higher probability of being alive at the end of follow-up period for WV-Medicare 
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cohort compared to the SEER-Medicare cohort indicates that a three years follow-up period may 
not produce sufficient robust statistical estimates as compared to longer follow up period to make 
any conclusions in this regards due to higher five-year survival in women with BC. 
Total Healthcare Costs of Breast Cancer in the Initial Phase (12-months) After Diagnosis 
 In this retrospective observational cohort study, the average total healthcare costs, the 
average total inpatient costs, and the average total costs for physician services in the initial phase 
of one year following BC diagnosis for the WV-Medicare cohort was significantly lower than 
that for the SEER-Medicare cohort.  In the multivariate framework, these differences shrunk but 
continued to remain significant.  In the WV-Medicare cohort, women who had regional or distant 
stage of BC, who had surgery with adjuvant therapy or who had adjuvant therapy only, who had 
inpatient visits, who had two or more comorbidities, and who had either depression or anxiety 
had significantly higher total average costs.  Also, in the WV-Medicare cohort women who were 
of age 75 or older had significantly lower total average costs.  In the Blinder-Oaxaca 
decomposition analyses, only 15.82% of the difference in the total average costs between the 
WV-Medicare and SEER-Medicare cohorts was explained by the beneficiary characteristics.  
Enabling resources (census tract income and education) contributed 6.85%, healthcare use (PCP 
visits, type of initial treatment, inpatient use) contributed 7.53%, and external healthcare 
environmental factors (location of residence, hospital visits) contributed 3.33% to the total 
explained portion of 15.82%.  A total of 84.14% of the differences in the total average costs in 
the initial phase of care between WV-Medicare and SEER-Medicare cohorts remained 
unexplained.  The study findings indicate that a portion of the lower costs in a rural state such as 
WV as compared to the SEER-Medicare regions may be due to the differences in the Medicare 
spending across various geographic regions in the US 
44
.  Also, these findings are surprising 
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given the higher comorbidity burden which should increase the total average costs in the initial 
phase following BC diagnosis.  Furthermore, the study findings highlight the importance of 
encouraging elderly WV women to utilize preventive screenings to get BC diagnosis at earlier 
stages.  These also emphasize the importance of better co-management of physical and mental 
chronic conditions in this rural and elderly population, to lower overall costs to Medicare in a 
rural WV state.  The findings from the Blinder-Oaxaca decomposition analyses indicate that a 
larger portion of ‘unexplained’ differences may be due to unmeasured factors such as health 
status, severity of comorbid conditions, BMI, patient preferences and propensity to seek care. 
CONCLUSION 
 This project laid the foundation or larger studies aimed at reducing and eliminating BC 
disparities in a rural and geographically challenged state such as WV whose population is aging 
and has lower socio-economic status.  Given that the elderly WV women had lower incidence of 
BC but higher BC-related mortality as compared to the national estimates 
13,14
, various factors 
such as mammography screening, timeliness of care, appropriateness of care, physical access to 
healthcare services and healthcare professionals need to be studied to determine if these factors 
are the contributors to these disparities.  In this project, the association between persistence with 
mammography screening and stage at BC diagnosis, timeliness of BC care based on published 
opinion-based recommendations, and total average costs in the initial phase were evaluated and 
estimated to identify if these factors contributed to the higher BC-related mortality in the rural 
state and if these rural women bore higher costs in the initial phase.  The study findings directed 
that only timely diagnosis of BC as per published recommendations is an issue in rural WV, 
however the chances of survival were better in this population as compared to the estimates from 
their national counterparts.  Various unmeasured factors such as health status, BMI, severity of 
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comorbid conditions, patient preferences, social and cultural barriers to care and several 
physician related and health system factors may be contributing to higher BC-related mortality in 
elderly WV women. 
FUTURE RESEARCH 
 Studies investigating the effect of long term persistence with mammography screening 
(e.g. 10-years) on stage at BC diagnosis after controlling for important covariates such as health 
status, BMI, patient preferences, and beliefs knowledge about mammography screening that may 
generate a clear picture about the beneficial effects of mammography screening in this rural and 
elderly population are suggested.  In addition, studies which controls for various factors such as 
fear, sense of fatalism, knowledge and beliefs about BC, perceived risk, physicians’ 
characteristics, and health system factors which may affect timely BC care are advocated.  
Furthermore, studies evaluating the effect of timely BC care on survival in elderly women should 
include longer follow-up period of at least five to ten years to produce accurate conclusions 
about this association.  Future research focusing on the incremental costs due to presence of 
various co-occurring chronic conditions among elderly population with BC from rural areas is 
also recommended.  Moreover, studies estimating indirect medical costs, indirect non-medical 
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